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Type 2 diabetes mellitus (T2DM) is a nation-wide prevalent chronic condition, which includes 
direct and indirect healthcare costs. T2DM, however, is a preventable chronic condition based on 
previous clinical research. Many prediction models were based on the risk factors identified by 
clinical trials.  One of the major tasks of the T2DM prediction models is to estimate the risks for 
further testing by HbA1c or fasting plasma glucose to determine whether the patient has or does 
not have T2DM because nation-wide screening is not cost-effective.  
 
Those models had substantial limitations on data quality, such as missing values. In this 
dissertation, I tested the conventional models which were based on the most widely used risk 
factors to predict the possibility of developing T2DM. The AUC was an average of 0.5, which 
implies the conventional model cannot be used to screen for T2DM risks. Based on this result, I 
further implemented three types of temporal representations, including non-temporal 
representation, interval-temporal representation, and continuous-temporal representation for 
building the T2DM prediction model. According to the results, continuous-temporal representation 
had the best performance. Continuous-temporal representation was based on deep learning 
methods. The result implied that the deep learning method could overcome the data quality issue 
and could achieve better performance.  
 
This dissertation also contributes to a continuous risk output model based on the seq2seq model. 
This model can generate a monotonic increasing function for a given patient to predict the future 
probability of developing T2DM. The model is workable but still has many limitations to 
overcome.  
 
Finally, this dissertation demonstrates some risks factors which are underestimated and are worthy 
for further research to revise the current T2DM screening guideline. The results were still 
preliminary. I need to collaborate with an epidemiologist and other fields to verify the findings. In 
the future, the methods for building a T2DM prediction model can also be used for other prediction 
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Chapter 1: Introduction 
 
Electronic health records (EHRs) are now being created, modified, used, and viewed by multiple 
entities such as primary care, hospitals, insurance companies, and patients. More and more medical 
information, including the patients’ health information, records of clinical decision-making, and 
prescriptions, is collected and documented. The data volume of EHRs has increased exponentially 
over the past several years. Besides the data volume, data complexity is also a challenge. The data 
complexity comes from the knowledge domain, such as the meaning of the variable, representing 
the variable, and using the temporal information in the dataset. For those challenges, machine 
learning is a potential approach to learn some information from the complex dataset.  
 
Because the EHR is a longitudinal record, different temporal representations can describe different 
aspects of temporal information in the EHR, which can assist us in understanding the importance 
of a particular variable with or without considering the previous information. Three temporal 
representations were applied to this research. The research not only tests different types of 
temporal representations but also creates a novel prediction model that can estimate a continuous 




















Chapter 2: Literature Review 
 
Chapter 2.1: The Definition of Diabetes Mellitus and Diagnostic Criteria 
 
Diabetes mellitus (DM) is a wide-spread chronic disease. In this section, I will generally 
introduce the definition of diabetes mellitus and its diagnostic criteria.  
 
Chapter 2.1.1: What is Diabetes Mellitus? 
 
Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia resulting 
from a deficiency of insulin action, insulin secretion, or both. Diabetes mellitus can be classified 
into four general categories 1) Type one diabetes mellitus (T1DM), 2) Type two diabetes mellitus 
(T2DM), 3) Gestational diabetes mellitus (GDM), and 4) Specific types of diabetes due to other 
causes[1]. Type one diabetes is caused by autoimmune beta-cell destruction leading to absolute 
insulin deficiency. Type two diabetes is due to a progressive loss of beta-cell insulin secretion 
frequently accompanied by insulin resistance.  GDM is generally diagnosed in the second or third 
trimester of pregnancy. In addition, patients with GDM have a high probability of developing 
T2DM within the next several years[2]. Other types of diabetes are caused by monogenic defects, 
disease of the exocrine pancreas, drugs, or chemicals. Among four different categories of diabetes, 
both type one and type two are major concerns. Currently, DM can be diagnosed by some of the 
methods described below. 
 
Chapter 2.1.1: Current Diagnostic Criteria of Diabetes Mellitus 
 
In 1997, the first Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 
revised the diagnostic criteria by evaluating the three cross-sectional epidemiological studies 
which focused on fasting plasma glucose (FPG) levels and the presence of retinopathy[3]. 
Retinopathy is the key factor which determines the acceptable threshold of a glucose level. The 
three studies confirmed the long-standing diagnostic 2-h plasma glucose (2-h PG) value over 
200mg/dL led to a significant increase in the risk of developing retinopathy. The older FPG value, 
140 mg/dL, was noted to identify far fewer individuals with diabetes than the 2-h PG criteria. The 
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committee decided to reduce the value of FPG from 140 mg/dL to 126 mg/dL. In 2009, the 
International Expert Committee recommended the use of the Hemoglobin A1c (HbA1c) test to 
diagnosis DM, with the threshold over 6.5%, and confirmed by American Diabetes Association 
(ADA)[4]. Patients who present with severe hyperglycemic symptoms or hyperglycemic crisis can 
be diagnosed by random plasma glucose (RPG) over 200 mg/dL. All criteria are listed in table 1.  
Table 1.The Diagnostic Criteria of DM 
Test Name Range Criteria  
FPG >= 126 mg/dL (7.0mmol/L) Fasting is defined as no caloric intake for at least 
eight hours. 
2-h-PG >=200mg/dL (11.1mmol/L) Using 75 grams anhydrous glucose is dissolved in 
water. 
HbA1c >=6.5%(48 mmol/mol) The method should be certified by NGSP and 
standardized DCCT assay. 
RPG >=200mg/dL (11.1mmol/L) Patients should present severe hyperglycemic 
symptoms or hyperglycemic crisis. 
 
Chapter 2.2: The Prevalence and Economic Burden of DM in the U.S. 
In this section, I will review the articles related to the prevalence of DM and the economic burden 
in the U.S. 
 
Chapter 2.2.1: The Prevalence of Diabetes Mellitus in the U.S. 
 
Several studies, such as the National Health Interview Survey (NHIS)[5], National Health and 
Nutrition Examination Survey (NHANES)[6], and Behavioral Risk Factor Surveillance System 
(BRFSS) [7], are used to examine the prevalence and the incidence of DM in the U.S.. These 
survey programs are sponsored by the Centers for Disease Control and Prevention (CDC). NHIS 
is a large-scale cross-sectional household interview survey. NHIS collects information on 
population disease prevalence, extent of disability, and use of health care services. The prevalence 
information is based on self-reported diagnosis and other data. NHANES combines interviews and 
physical examinations. The examinations include medical, dental, and physiological 
measurements, including laboratory tests. The Behavioral Risk Factor Surveillance System 
(BRFSS) uses nation-wide health-related telephone surveys that collect U.S. resident data 
regarding their health-related risk behaviors, chronic health conditions, and use of preventive 
services. This system currently collects 400,000 adult interviews each year in all 50 states. The 
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previous research focused on the residents in the U.S. including all ages, races, and genders. The 
SEARCH for Diabetes in Youth was initiated in 2000 and funded by the CDC for researching the 
incidence and the prevalence of diabetes for 0-19 years[8]. SEARCH primarily focuses on the 
association between DM and DM-related risk factors including biological and socio-cultural risk 
factors, quality of life, and mortality.   
  
In the U.S., the CDC utilizes the NHIS to estimate the incidence of diagnosed diabetes including 
T1DM and T2DM. The incidence of self-reported diabetes in 2012 was 0.71%, up from 0.35% in 
1990.[9]. The incidence rate doubled in 12 years. Before 2016, the NHIS did not include a 
supplemental question to distinguish T1DM or T2DM. There was no prevalence rate for T1DM 
and T2DM before 2016. In 2016, the prevalence rate in U.S. adults of T1DM was 0.55%, 
representing 1.3 million adults. Twenty-one (21) million U.S. adults were diagnosed with T2DM, 
equal to 8.6% of the U.S. adult population. Three point three percent (3.3 %) of U.S. adults were 
diagnosed with other types of DM[10].  
 
Dr. Menke utilized NHANES to estimate the trend of DM and the prevalence in 2012 in the U.S. 
His team indicated that from 1988 to 2012, the age-standardized prevalence in the U.S. increased 
from 9.8% in1988-1994 to 10.8% in 2001-2002 to 12.4% in 2011-2012[11]. The upward trend 
appeared in age groups, genders, racial/ethnic groups, and all education levels. The same dataset 
also indicated sixty-four percent of DM patients were diagnosed, others were undiagnosed. In all 
races, Hispanics have the highest age-standardized prevalence (22.6%)[12].  
 
Dr. Mokdad used the BRFSS data in 2000 to estimate prevalence of DM from 184,450 adults 
enrolled in this dataset. The estimated prevalence was 9.7%[13]. From the website of BRFSS, the 
crude prevalence of DM increased from 9.5% in 2011 to 10.5% in 2016. In 2011, Mississippi 
(12.4%), South Carolina (12.1%), West Virginia (12.0%) were the top three states with the highest 
crude prevalence. West Virginia (15.0%), Alabama(14.6%), and Mississippi(13.6%) had the most 
DM patients in the 2016 BRFSS survey data[13].  
 
Currently more and more young patients develop diabetes. In 2009, the SEARCH for Diabetes in 
Youth Study indicated the prevalence of DM in youths under the age of 20 was 0.2%[14]. Among 
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those patients, 86% of them had T1DM, 10.8% of them had T2DM, with the remainder suffering 
from other diabetes types. Based on this study, the researchers estimated 191,986 U.S. youth under 
the age of 20 had diabetes in 2019. Most of them were diagnosed with T1DM.  
 
Chapter 2.2.2: The Economic Burden of DM in the U.S. 
 
The American Diabetes Association (ADA) published the economic cost of DM in the U.S. every 
five years beginning in 2007[15]. The 2007 report includes both national level and state-level data 
from NHIS, NHANES, Medical Expenditure Panel Survey (MEPS), National Inpatient Sample 
(NIS), National Ambulatory Medical Care Survey (NAMCS), Ingenix MCURE database, National 
Hospital Ambulatory Medical Care Survey (NHAMCS), National Nursing Home Survey (NNHS), 
and National Home and Hospice Care Survey (NHHCS). In 2012[16], ADA added the American 
Community Survey (ACS), Behavioral Risk Factor Surveillance System (BRFSS), 
Optumlnsight’s de-identified Normative Health Information database (dNHI), the Medicare 5% 
sample Standard Analytical Files (SAFs), and Current Population Survey (CPS) into the 2007 
study’s datasets. In a recent publication, the ADA added the Medicare Current Beneficiary Survey 
(MCBS) into the 2012 study datasets. 
 
In 2007, the ADA utilized the NHIS (2004-2006) and NNHS (2004) to estimate the prevalence in 
different age groups, sex, and race/ethnicity. The NHIS was applied to estimate the prevalence of 
noninstitutionalized people. The ADA assumed the prevalence rate of DM of institutionalized 
people was the same as noninstitutionalized people. The NNHS was utilized for analyzing the 
prevalence of DM in nursing homes. The previous two datasets focused on diagnosed DM rather 
than undiagnosed DM. The NHANES, combining interview and physical examinations, was used 
to estimate undiagnosed prevalence. Based on the prevalence rate found in the previous three 
datasets, the ADA further interpreted prevalence rate by merging U.S. Census Bureau population 
estimates (2007) for a more accurate estimation of the national prevalence rate. After identifying 
the national prevalence rate, ADA analyzed the medical cost for diabetes. For direct medical costs, 
the ADA adapted MEPS for outpatient and the NIS for inpatient. For adjusting etiological fractions 
which are important to analyze the attribution of health resource cost, the ADA decided to use 
MCURE, a medical claim dataset enrolling 16.3 million beneficiaries in 2006. This resulted in 
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relative attributions of health resources and costs for different medical conditions. These relative 
attributions were applied to the NAMCS, NHAMCS, NHHCS, NNHS, and NHIS to estimate the 
indirect costs of DM In 2012, ADA merged dNHI, a new dataset from MCURE database and SAFs 
for adjusting etiological fractions. Moreover, the ADA started to use ACS and BRFSS to estimate 
the prevalence rate of DM in the U.S. The ADA also decided to combine NHIS and CPS for more 
precise estimation of the loss of national productivity. In 2017, ADA added MCBS for more 
accurately estimation of prevalence rate of DM of state level[17].  
The total estimated direct and indirect costs of T2DM are listed in the table 2. Each category 
includes the detail cost estimation of each major category. 
 
Table 2. The Estimated Economic Burden of DM in the U.S. 
Summary Year  






Total cost incurred by people with 
DM 
205 billion  673 billion  414 billion 
Total cost incurred by people with 
DM attributed to DM 
116 billion  361 billion 237 billion 
Total indirect cost of people with DM 58 billion  69 billion 89.9 billion 
Health Care expenditures    
Institutional care  65 billion  90 billion 76 billion 
Outpatient care 23 billion 31 billion 53 billion 
Outpatient medications and supplies 28 billion 52 billion 106 billion 
Chronic complications     
Neurological 3.5 billion 4.8 billion Not provided 
Peripheral vascular  3.0 billion 3.8 billion Not provided 
Cardiovascular  22.4 billion 22.4 billion Not provided 
Renal  3.6 billion 5.2 billion Not provided 
Metabolic 0.22 billion 0.35 billion Not provided 
Ophthalmic 1.04 billion 1.8 billion Not provided 
 
Chapter 2.3: The Medical Backgrounds of T2DM 
In the previous two sections, I focused on what is DM and the severe current condition of DM. In 
this section, I will give more attention to T2DM because T2DM is preventable. The following 




Chapter 2.3.1: The Disease Path of T2DM 
 
Prediabetes is a state of dysglycemia that precedes the development of T2DM[18]. Insulin 
resistance and beta cell dysfunction are both key etiological determinants of prediabetes and 
diabetes[19]. The concurrent deterioration in whole-body insulin resistance and beta cell secretion 
can determine the transition from normal glucose tolerance (NGT) to impaired glucose tolerance 
(IGT) over T2DM[20]. The distinct trajectories between whole-body insulin resistance and beta 
cell function on individuals found to have diabetes is based on elevated FPG versus elevated 2-h 
PG during the 75-g OGTT[21]. Insulin sensitivity declined more rapidly in individuals 
accompanied with elevating 2-h PG by OGTT before diagnosing T2DM[22]. In contrast, beta cell 
secretion was significantly decreased in the subgroups of T2DM with concurrent increasing FPG 
before receiving T2DM diagnosis[23]. The phenomena of elevated FPG is called impaired fasting 
plasma glucose (IFG), and the inflated OGTT is named as impaired glucose tolerance (IGT). In 
previous studies, IFG is more associated with hepatic insulin resistance and excessive endogenous 
glucose production[24] than IGT, which is characterized by skeletal muscle insulin resistance[25]. 
In addition, subjects with IGT have impaired first and second phase insulin secretion and IFG 
presents as an isolated defect in first-phase secretion[26]. Individuals in the period of IFG or IGT 
are considered as prediabetic patients[27]. Prediabetes is a general term to represent the condition 
between normal glucose tolerance (NGT) and diabetes. Prediabetes is associated with a variety of 
disorders usually considered with diabetes.  
 
Chapter 2.3.2: The Risk Factors and Complications Associated with T2DM 
 
From the World Health Organization definition, a risk factor is any attribute, characteristic or 
exposure of an individual that increases the likelihood of developing a disease or injury[28]. The 
definition of complication is an unanticipated problem that arises following, and is a result of, a 
procedure, treatment, or illness. Combined with the disease path of diabetes, the risk factors of 
T2DM might be the complications of prediabetes. The following section will illustrate the risk 
factors, and complications of prediabetes and T2DM.  
 
Risk factors associated with T2DM can be roughly divided into modifiable risk factors and 
irreversible risk factors. Reversible risk factors include overweight/obesity, physical inactivity, 
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hypertension, abnormal lipid profile, and socio-economic status[29]. Irreversible risk factors are 
comprised of demographic factors, including age, gender, race/ethnicity, genomic, and family 
history[30]. Prediabetes is currently considered to have a strong correlation with cardiovascular 
disease, periodontal disease, cognitive dysfunction, retinopathy, neuropathy, nephropathy, 
obstructive apnea, hypogonadism, and metabolic syndrome[31]. 
 
For modifiable risk factors, the following studies provide the association between those risk factors 
and T2DM. Several studies indicated weight reduction significantly decreasing the possibility of 
developing T2DM. Those studies were conducted across several countries including U.K., U.S.A, 
Canada, Australia, Germany, Finland, the Netherlands, Singapore, Sweden, and China[32]. 
According to the CDC 2017 National Diabetes Statistics Report, based on 2011-2014 NHANES, 
87.5% adults diagnosed with T2DM were overweight or obese[33]. Among those people 
diagnosed with diabetes and overweight/obesity, 26.1% were overweight, 43.5% were obese, and 
others were severely obese. MEPS provided another data source for profiling the correlation 
between physical inactivity and diabetes. Compared with normal-weight active adults, the 
multivariate adjusted odds ratio for diabetes was 1.52 for normal-weight inactive adults and 1.65 
for overweight inactive adults[34]. Many years ago, several studies indicated hypertension is a 
significant predicator of T2DM. Those studies were prospective studies with large cohorts. 
Abnormal lipid profile including increased total cholesterol and reduced HDL increases the risk 
of developing T2DM. Recently, fasting triglycerides are a new predictor of diabetes. Socio-
economic status is usually associated with physical inactivity, a lack of fresh fruit and vegetables, 
overweight/obesity, and smoking which are all dominant risk factors for developing T2DM.  
 
The irreversible risk factors of T2DM, including gender, race, age, and ethnicity, have different 
contributions to different types of DM. The T2DM incidence rate is increasing in youth, especially 
among some racial and ethnic groups with a disproportionately high risk for developing T2DM 
and its complications: American Indians, African Americans, Hispanic/Latinos, Asians, and 
Pacific Islanders. Older age is highly correlated with risks for developing T2DM. Males have a 
slightly higher prevalence rate than females. A group of subsets of genetic variants are associated 
with T1DM and T2DM. Genome-wide association studies have identified 130 genetic variants 
associated with T2DM, glucose levels, or insulin levels, but those variants just explained 15% of 
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disease heritability[35]. Most T2DM variants are located in noncoding genomic regions. Some 
variants, such as KCNQ1, had strong parent-of-origin effects[36]. Unfortunately, most known 
T2DM genetic variants were less successful than clinical risk factors (BMI, family history, glucose) 
for identifying those at future risk for developing T2DM[37]. Family history of T2DM is still an 
important risk factor. Based on the InterAct study, prominent lifestyle, anthropometric, and genetic 
risk factors could explain only a marginal proportion of family history-associated excess risk[38]. 
The result inferred family history still remains a strong, independent, and easily assessed risk factor.  
 
Chapter 2.3.3: The Association Between Diseases and Prediabetes 
 
Prediabetes is the chronic condition which has a high possibility of developing T2DM in the future 
but can be reversed by appropriate treatment or life style change. Several diseases have been 
demonstrated to be associated with prediabetes. Understanding those relationships between those 
diseases and T2DM can find some targets for preventing T2DM. 
 
Chapter 2.3.3.1: The Association Between Cardiovascular Disease and Prediabetes 
 
Several studies across different countries presented a strong relationship between prediabetes and 
cardiovascular diseases. In the Whitehall study, the risk of cardiovascular disease was almost 
double within subjects with IGT, then NGT[39]. Coutinho and colleagues carried out a meta-
analysis enrolling 95,000 individuals followed for 12 years which recognized the correlation 
between blood glucose and cardiovascular disease events[40]. The Austrian Diabetes, Obesity and 
Lifestyle Study found cardiovascular disease mortality increased 1.6 times among patients with 
IFG[41]. Ford and fellow researchers published a systematic review to examine the relationship 
between prediabetes and CV risk[42]. The systematic review concluded the relative risk (RR) of 
cardiovascular disease of IFG between 1.18 and 1.20. The RR of IGT was 1.20. Patients have IFG 
and IGT where the RR of cardiovascular disease was 1.1. However, CV risks are not the only 
ones[42]. 
Chapter 2.3.3.2: The Association Between Circulatory Disease and Prediabetes 
 
Circulatory problems include retinopathy and neuropathy. Retinopathy is a common complication 
of T2DM. In a study relating FPG and retinopathy, no clear threshold could be identified as the 
point at which patients without diabetes (FPG< 7.0mmol/l) would be in danger of retinopathy 
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occurring. The prevalence of retinopathy with the FPG below 5.6 mmol/l ranged from 7-13 
percent[43]. For those with an age above 40, either FPG over 5.8 mmol/l or HbA1c above 5.5% 
resulted in a significant increase in prevalence. Neuropathy is common in diabetic patients. Newly 
diagnosed diabetic patients roughly with 1.18 -1.25 times have developed neuropathy compared 
with non-T2DM patients. This phenomenon, considering the progress of DM, implied the 
neuropathy might happen in the period of prediabetes. Chronic kidney disease (CKD), 
characterized by albuminuria or reduced kidney function, is highly prevalent in diabetic and 
prediabetic patients. A decrease in glucose tolerance steeply increased the prevalence CKD in a 
population-based study. This study indicated the prevalence of CKD, compared with the non-
diabetic group, increased from 1.2% with the FPG between 4.94 and 5.27 mmol/l to 4% when the 
FPG is over 5.66mmol/l[44]. A study based on NHANES (1999-2006) indicated 17.7% of 
prediabetic patients had CKD compared with only 10.6% of non-diabetic individuals[45].  
Chapter 2.3.3.3: The Association Between Hypogonadism and Prediabetes 
 
There is a bidirectional relationship between T2DM and male hypogonadism[46]. Cross-sectional 
studies demonstrated that 25-40% of males with DM also had low testosterone levels[47]. Reduced 
levels of testosterone have also been associated with insulin resistance[48]. Male individuals with 
low testosterone also have a higher possibility of developing DM[49]. One study examined 221 
middle-aged, male individuals without diabetes and identified an inverse association between 
testosterone, FPG, and insulin resistance which is independent of body fat or abdominal fat[50].  
The relationship between insulin resistance and testosterone raised the question of whether or not 
there is a link between prediabetes and testosterone. Few studies have focused on this question. A 
community-based cross-sectional study conducted by Goodman and colleagues examine the 
association between androgen levels and glucose tolerance of male individuals over 55[51]. They 
also found men with IFG or IGT had substantially lower total testosterone levels adjusted by age 
and BMI. Another cross-sectional and longitudinal study investigated the impact of IFG on sexual 
dysfunction[52]. Metabolic syndrome is associated with many diseases such as CVD and T2DM. 
In addition, there is an overlap in the presence of prediabetes and metabolic syndrome[53].   
Chapter 2.3.3.4: The Association Between Other Conditions and Prediabetes 
 
Obstructive sleep apnea (OSA) is one type of sleep-disordered breathing (SDB) which is 
characterized by a cessation of breathing while sleeping. This symptom is associated with T2DM, 
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metabolic syndrome, hypertension, CVD, and insulin resistance[54]. OSA is believed to contribute 
to IGT and insulin resistance. Twenty to sixty-seven percent of pre-diabetic patients also have 
OSA [55]. Alshaarawy and colleagues utilized the NHANES dataset to answer the relationship 
between SDB and prediabetes[56]. They evaluated 5,685 participants without diabetes and 
indicated patients had more than 3 biomarkers of SDB, such as sleep duration less than 6 hours, 
snoring, snorting, and daytime sleepiness, whose odds ratio of prediabetes were 1.6. Periodontal 
disease is a prevalent complication of diabetes. Several studies indicated subjects with IGT had 
severe periodontal inflammatory disease. However, other studies pointed out individuals with IGT 
and NGT presented an identical periodontal status. Chronic hyperglycemia contributes to cognitive 
dysfunction[57]. Clinically relevant diabetes-related cognitive decrements occur in two periods, 
one in brain development in childhood, and another in aging when the brain undergoes 
neurodegenerative changes. Hyperglycemia, in the absence of diabetes or IGT, has been 
demonstrated to be associated with lower memory and reduced hippocampal volume[58]. Tan and 
colleagues indicated diabetes and prediabetes, characterized by insulin resistance, hyperglycemia, 
and hyperinsulinemia, were associated with decreased brain volume and reduced cognitive 
function when presented in middle age[59]. 
 
Chapter 2.4: Some Biomarkers for Diabetes and Prediabetes 
 
The definition of biomarker has changed over time. In 1998, the National Institutes of Health 
defined the biomarker as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention”[60]. WHO further extended this definition as “almost any measurement 
reflecting an interaction between a biological system and a potential hazard, which may be 
chemical, physical, or biological. The measured response may be functional and physiological, 
biochemical at the cellular level, or a molecular interaction”[60]. In the clinical world, biomarkers 
encompass everything from pulse and blood pressure through basic biochemistries to more 
complicated laboratory results from blood or tissues. Biomarkers can be considered as surrogate 
endpoints which represent health status. There are two requirements for biomarkers, one is 
relevance and the other validity. Relevance is the biomarker informing clinical information which 
can be used in clinical decision. Validity is the necessity of this biomarker for the endpoint[61].  
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In addition to the pancreas, the liver also plays an important role in blood glucose homeostasis. 
The liver is an important organ controlling gluconeogenesis, and it is also a target of end organ 
damage from hyperinsulinemia[62]. Several biomarkers are associated with liver damage such as 
alanine aminotransferase, gamma-glutamyl transferase, ferritin, plasminogen activator inhibitor 1, 
tissue plasminogen activator antigen, C-reactive proteins, and triglycerides[63]. Those biomarkers 
were increased in patients with dysglycemia before the diagnosis of T2DM. Some novel potential 
biomarkers, from a nested case-control study of over 6000 patients, revealed several novel 
biomarkers for T2DM such as adiponectin, CRP, ferritin heavy chain 1, interleukin-2 receptor 
A[64]. Another study pointed out leptin, renin, IL-1RA, hepatocyte growth factor, fatty acid 
binding protein 4, and tPA were associated with insulin resistance. However, a systematic review 
indicated those novel biomarkers cannot provide substantial improvement for a prediction model 
compared with well-known risk factors such as glucose, physical inactivity, and others[65].  
 
Several studies inferred correlations between some biomarkers and prediabetes. Those biomarkers 
were adiponectin, interleukin-1-receptor antagonist, metabolomics, fructosamine, and glycated 
albumin, and Fetuin-A[66]. Adiponectin is a protein hormone produced by adipocytes which has 
both insulin-sensitizing and anti-inflammatory effects. A case-control study analyzed the level of 
adiponectin over time prior to diagnosis of T2DM where T2DM patients had a lower level of 
adiponectin compared with non-T2DM patients over 13-year follow-up period[67]. Another 
prospective study enrolled and followed up 5,085 IFG individuals over 4.4 years[68]. Male and 
female subjects with the lowest adiponectin were 1.78 and 2.17 times likely, respectively, of 
developing T2DM compared with those with the highest levels[68]. The interleukin-1-receptor 
antagonist produced by adipocytes acts as a competitive inhibitor of Interleukin-1beta for its 
receptor. Interleukin-1beta not only inhibits beta-cell function but also promotes beta-cell 
apoptosis. In a nested case-control study subjects diagnosed with T2DM had a higher level 
Interleukin-1-receptor antagonist up to 13 years prior to diagnosis with steep increases up to 6 
years prior to diagnosis[69]. In the Framingham Offspring Study, 61 profiled metabolites within 
378 subjects, half with DM and half without, three branched-chain amino acids and two aromatic 
amino acids had higher concentrations up to 12 years before developing T2DM[70]. The KORA 
cohort study pointed out lysophosphatidylcholine (LPC) 18:2, and acetylcarnitine were higher in 
patients with IGT[71]. The EPIC-Potsdam study confirmed results of LPC 18:2. EPIC-Potsdam 
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also pointed out sphingomyelin C16:1, and five species of acyl– alkyl phosphatidylcholines were 
associated with increased T2DM risk[70]. Fructosamine is the measurement of glycated total 
serum protein. Fructosamine and glycated albumin are the indicators of short-term glycemic 
control. The ARIC study analyzed the association between fructosamine and incident DM which 
pointed out patients with elevated 95th percentile at baseline with higher possibility of developing 
DM[72]. Fetuin-A is a glycoprotein secreted by the liver which acts as inhibitor of insulin receptor 
in the live and skeletal muscles. Stefan and colleagues found higher level of Fetuin-A were 
associated with IGT, insulin resistance, and increased liver fat[73]. Ou and colleagues selected a 
group of non-diabetic patients, 510 age- and sex- matched, with IGT had higher level of Fetuin-A 
compared with NGT[73]. 
 
Chapter 2.5: The Duration of Prediabetes 
Several studies tried to identify the average duration of prediabetes which can determine whether 
clinicians have enough time to delay the onset of diabetes or cause the patient to revert to NGT. 
Bertram My and colleagues found the average duration of prediabetes was 8.5 years in males aged 
over 30 and 10.3 years in female aged over 30[73]. Jared and colleagues enrolled 3,628 individuals 
aged 18-30 years and followed them for 25 years. They found the average duration of prediabetes 
was 9.5 years[75]. Mohammed and colleagues identified the average duration of prediabetes was 
1.9 years[76]. Based on those studies, clinicians might have sufficient time to delay or prevent the 
progression to diabetes.  
 
Chapter 2.6: T2DM Intervention and Prevention 
 
It is important to identify persons at risk for the development of T2DM as early intervention can 
delay or prevent the full onset of diabetes [32,77]. Several studies demonstrated applying lifestyle 
intervention, pharmacologic therapies, or bariatric surgery can augment insulin sensitivity and 
prevent beta-cell work overload[78,79]. In addition, when individuals decrease 5% of their body 
weight, total body insulin sensitivity can improve by 30% [80]and the probability of developing 
T2DM can be reduced by 58%[81]. Individuals enrolled in the Finnish Diabetes Prevention Study 
were instructed to lose weight (>5% of total body weight), reduce total fat consumption (<30% of 
total calories), increase fiber consumption (15 g for each 1000 kilocalories), and extend physical 
activity time (30 min/d)[82]. They were followed for 3.2 years. People who complied with the 
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instructions had lower cumulative diabetes incidence compared with the control group[83]. Other 
studies such as the Da Qing study[84], Diabetes Prevention Program[81], The Indian Diabetes 
Prevention Program[85] confirmed these results. Some studies indicated drug interventions such 
as metformin[81,85], rosiglitazone[86], and acarbose[87] can also reduce the incidence of T2DM.  
 
Chapter 2.3.7: Diabetes Prediction Models Overview 
As stated previously, there are several risk factors for T2DM which overlap with prediabetes. All 
of those findings suggest that using those risk factors to develop a T2DM prediction model can be 
used to delay or prevent T2DM as early as possible. There are major three types of T2DM 
prediction models: 1) prediction of the onset of T2DM, 2) prediction of the short-term 
complications, and 3) prediction of the long-term complications. Models of prediction of the onset 
of T2DM are comprised of two major categories: 1) diagnostic prediction model, and 2) prognostic 
prediction model. The diagnostic prediction model can predict, for a given patient, the presence or 
absence of T2DM. In contrast, a prognostic prediction model of T2DM predicts the possibility of 
patients developing T2DM over the following several years. Diagnostic prediction models utilized 
the data backward from the time of diagnosis to identify the disease path. Diagnostic prediction 
models can also be applied for prevalence estimation, predicting the current diagnosis, and 
identifying undiagnosed patients. Prognostic prediction models adapt currently available data for 
predicting the risks within a specific period. Prognostic prediction models can be implemented for 
assisting patients to understand future risks, as well as allowing time for lifestyle changes to 
prevent or slow the disease. Currently, there are 18 T2DM diagnostic prediction models which are 
listed in table 3 and 17 T2DM prognostic prediction models which are presented in table 4. 
Table 3. The Name of T2DM Diagnostic Prediction Models, Number of Patients, and 
Performance 
Study Name Number of Patients Performance 
American Diabetes Risk Score[88] 3,770 AUC 0.78 
Brazilian Simple Prediction Model[77] 1,224 AUC 0.77 
Cambridge Risk Score[90] 1,077 AUC 0.80 
Chinese Diabetes Risk Score[91] 4,336 AUC 0.64 
Danish Risk Score[92] 6,784 AUC 0.80 
Diabetes Risk Calculator[93] 7,092 AUC 0.85 
FINDRISC[94] 4,435 AUC 0.87 
DPP questionnaire modified[95] 435 AUC 0.80 
Dutch Diabetes Risk Score[96] 1,434 AUC 0.78 
German Diabetes Risk Score[97] 25,167 AUC 0.84 
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Study Name Number of Patients Performance 
Indian Diabetes Risk Score[98] 2,350 AUC 0.69 
Indian Risk Score[87] 10,003 AUC 0.73 
Kuwaiti Risk Score[100] 562 AUC 0.82 
Oman Diabetes Risk Score[89] 4,881 AUC 0.83 
Patient Self-Assessment Score[102] 5,258 AUC 0.79 
Rotterdam Predictive Model[103] 1,016 AUC 0.74 
Spanish Diabetes Risk Score[104] 6,237 AUC 0.83 
Symptom-Risk Questionnaire[105]  2,364 AUC 0.80 
 
Table 4.The Name of T2DM Prognostic Prediction Models, Number of Patients, and 
Performance 
Study Name Number of Patients Performance 
San Antonio Diabetes Risk Score[106] 2,903  AUC 0.85 
Chinese Diabetes Risk Score[107] 2,960  AUC 0.702 
DESIR Diabetes Risk Score[108] 1,863 AUC 0.85 
Thai Diabetes Risk Score[109] 2,677 AUC 0.74 
Framingham Offspring Diabetes Risk 
Score[110] 
3,140 AUC 0.85 
QDScore[111] 2,540,753 D Score (Female 2.11, Male 
1.97) 
India Diabetes Risk Score[112] 3,094 AUC 0.70 
PROCAM Diabetes Risk Score[113] 3,737 AUC 0.79 
Rancho Bernardo Diabetes Risk[114] 
Score 
1,549 AUC 0.71 
Diabetes Population Risk Tool[114] 9,177 AUC 0.77 
AUSDRISK[115] 6,060 AUC 0.78 
KORA[116] 873 AUC 0.76 
BRHS[117] 6,927 AUC 0.77 
EPIC-Norfolk[118] 12,519 AUC 0.76 
Tromso[119] 26,168 AUC 0.84 
PREDIMED scores[120] 1,381  AUC 0.641 
Taiwan Risk Scores[121] 73,961 AUC 0.83 
 
Many previous studies have adapted logistic regression and survival analysis as two major tools 
for building T2DM prediction models. Other people tried to utilize several machine learning 
algorithms for building a T2DM prediction model. Those machine learning algorithms have been 
tested by the Pima Indian Diabetes dataset including eight variables and 768 individuals. The 
variables included times of pregnant, 2hr-OGTT, blood pressure, skinfold thickness, 2-hr serum 
insulin, BMI, family history of DM, and age. The results of each study are listed in Table 5.   
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Table 5. The Result of Pima Diabetes Dataset Over Different Machine Learning 
Algorithms 
Method  Accuracy Method Accuracy 
MFNNCA[122] 80.07% GRG2[123] 81.25% 
ANFIS[124] 98.14% GRNN[125] 80.21% 
MLP[125] 77.08% RBF[125] 68.23% 
ARTMAP-IC[126] 81.00% MEA[127] 80.07% 
GCS[128] 73.8% KNN[129] 77.0% 
CART[129] 72.8% MLP[129] 75.2% 
LVQ[129] 75.8% LDA[129] 77.5% 
CART-DB[130] 74.40% SSVM[131] 76.73% 
MKS-SSVM[131] 93.20% PCA-ANFIS[132] 89.47% 
LDA-ANFIS[133] 84.61% Naïve Bayes[134] 74.5% 
Semi Naïve Bayes [134] 76.0% C 4.5[134] 76.00% 
MLPNN[135] 91.53% ME[135] 97.93% 
MME[123] 99.17% ESOM[128] 78.4% 
 
After entering the big data era, more data and methods are available for building prediction models. 
The following section focuses on different aspects of developing a T2DM prediction model. The 
first part is types of datasets utilized, including, but not limited to, survey, clinical trials, electronic 
health records, and claim datasets. The second part examines the methods applied to the previously 
mentioned dataset types. Those methods encompass statistical methods, machine learning 
algorithms, and deep learning methods.  
 
Chapter 2.8: Data Types in Developing a T2DM Prediction Model 
 
The data sources for T2DM prediction model studies can be generalized into cohort studies, survey, 
EHR (EMR), claims data, and miscellaneous data types. The definition for cohort study is “an 
outcome, or disease-free study population first identified by the exposure or event of interest and 
followed in time until the disease or outcome of interest occurs.” Based on this definition, most 
previous T2DM prognostic prediction models are based on cohort studies. Those cohort-based 
prognostic studies can be divided into two categories. One is cohort derivation study and the other 
is cohort validation study. The difference between them is the study purpose. The purpose of a 
cohort derivation study is to develop a new prediction model. The cohort validation study tests and 
calibrates an existing model for general usage. Generally speaking, the data for a cohort derivation 
study comes from a clinical trial. The data for a cohort validation study is typically derived from 
another clinical trial, routine health checks, or a primary care database. The prediction model from 
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a cohort derivation study is usually summarized by risk scores. For example, the San Antonio 
Diabetes Risk Score was derived from the San Antonio Heart Study. This study originally collected 
data from patients with circulatory system diseases like hypertension, heart failure, and others. A 
survey is another data source for the T2DM prediction model. The National Health and Nutrition 
Examination Survey is an example of survey data. This survey is conducted by the CDC to identify 
the health and nutritional status of adults and children in the U.S. The advantages of these two 
types of data are low missing values and high completeness. However, the limitation of these two 
types of data are low sample size and other missing information due to variables designed prior to 
the data collection. EHR and claims data sets are not collected for research purposes. The 
advantages of those two types are high sample size and more comprehensive information. The 
main disadvantage is a high number of missing values.  
 
Chapter 2.9: Pros and Cons of EHR Data in Clinical Research 
 
EHRs provide opportunities to enhance patient care, improve clinical practice, and identify 
patients eligible for clinical research. EHRs, in addition, may assist in the assessment of whether 
new treatments, repurposed drugs, or innovative healthcare delivery models can improve outcomes 
and result in cost savings. However, even with the previously mentioned benefits, EHRs still have 
some disadvantages such as data quality and validation, high proportion of missing value, 
heterogeneity among systems, and system knowledge. This paragraph will review the pros and 
cons of EHRs and the different methods and applications between EHRs and traditional 
epidemiologic methods.  
 
EHRs have been widely utilized to support observational studies, either as stand-alone data or in 
combination with other datasets. In observational studies, EHRs can minimize the need for 
duplicate data collection and accumulate large amounts of medical information throughout the 
patient’s life by using the existing informatics infrastructure. In some countries, EHRs can link to 
other types of datasets such as general population health and lifestyle surveys, disease registries, 
and data collected by other sectors. EHRs can be used for monitoring post-marketing safety 
surveillance and signal detection because EHRs can provide realistic rates of events. National 
patient registries extract data from EHRs for evaluating the guideline adherence and effectiveness 
of performance improvement initiatives. EHRs, however, still have strong limitations for 
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prospective studies. For clinical trials, EHRs can generate a list of qualified patients for specific 
clinical research which is widely implemented. In clinical trials, there are two main categories. 
One is pragmatic trials which are designed for examining the effectiveness of interventions in real-
life practice conditions and another is explanatory trials which aim to test an intervention which 
can work under several optimal situations. The National Institutes of Health (NIH) Care Systems 
Research Collaboratory and the Patient-Centered Outcomes Research Institute have both applied 
EHRs on pragmatic trials. EHRs can also support conventional randomized controlled trials for 
collecting electronic case report forms when data collection is focused and limited to critical 
variables which are consistently collected in routine clinical care.  
 
The first limitation of EHRs is data quality and validation. One data quality problem with EHRs 
comes from coding inaccuracies or bias introduced by the selection of codes driven by billing 
incentives rather than clinical needs. Data quality issues can be further divided into data accuracy, 
data completeness, data consistency, and data credibility. The data accuracy problems come from 
coding errors. Internal validation and external validation can, to some extent, overcome this 
problem. Missing values are the key challenge for data completeness. Values may be missing 
because an event did not happen or external (e.g., imputation failure) or internal (e.g., patient 
refusal to provide data) factors. Generally speaking, there are three categories of missing values: 
data missing completely at random (MCAR), data missing at random (MAR), and data missing 
not at random (MNAR). Several methods can mitigate the effects of missing values including data 
triangulation, surrogate elements which represent missing variables of interest, and statistical 
methods. Statistical methods enroll complete case analysis, available case analysis, mean/mode 
substitution, regression imputation, multiple imputation, and maximum likelihood. Data 
granularity and data measures are two major aspects of data consistency. Data granularity refers 
to the degree of detail of a variable of interest within the EHR and the consistency of variable 
granularity across databases or secondary data sets. Data measures indicate the consistency of 
variable’s unit or reference range within the same dataset or across different datasets. Data 
credibility is defined as the overall plausibility or reliability of the data. The degree of data 
reliability is influenced by data sources, current domain knowledge, and user-perceived reality.  
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Chapter 2.10: The difference between Traditional Epidemiology Study and EHRs 
Epidemiology Study 
 
Current FDA recommended using EHR in clinical investigation[136] and combining real-world 
evidence to remove the barrier between clinical trials and clinical care[137]. From the current FDA 
perspective, there are several differences between EHR based trial and clinical trials. Rob Califf, 
FDA Commissioner, said” The most useful source of knowledge will come from randomization in 
the context of clinical practice”. Understanding the difference between EHR based trial and 
traditional clinical trial are helpful in explaining the results into the healthcare contexts. The table 
6. outlines the questions the EHR could and could not answer[138].  
 
Table 6.The difference of methods and applications between EHRs and traditional 
epidemiologic methods 
Design Factor Traditional Epidemiology Study EHRs Epidemiology Study 
Original 
Purpose 
Research; Primary data collection  Clinical care; Secondary data usage 
Cost More expensive Less expensive 
Access Public Restricted 
Study Design Prospective cohort, nested case-control, 
cross-sectional 
Prospective or retrospective cohort, 
nested case-control, cross-sectional less 
common 
 
Time Frame Waiting until outcomes occur; restricted 
by funding 
Restricted by date of EHR 
implementation 
 
Population Based on recruitment; fewer participants; 
bias from incentives or healthy volunteer 
effects 
 
Based on healthcare system; more 
participants; various population 
Family Data Sometimes available Available  
Follow-up Scheduled with specific timing; restricted 
by funding 
Occurs during health care encounters; 






Established protocol; robust approach for 
data collection; with primary focus and 
specific measurements 
Recorded during encounter with varying 
levels of detail; stored in diagnosis, 




Any outcomes and all severities as 
documented at beginning with clear 
ascertainment 
 
Only outcomes requiring care by 
physician; missing value 
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Design Factor Traditional Epidemiology Study EHRs Epidemiology Study 
Outcome 
Ascertainment 
Consistent outcome definition over all 
participants 
Based on physician-specific diagnosis, 
and other enriched information e.g., lab 






Prespecified variables Whole EHR but not random, confounded 





Prespecified variables Limited or missing 
Internal 
Validity 
Attrition: Participants must return for 
study visits. 
Statistical regression: Participants with 
extreme initial values will regress toward 
the mean on subsequent visits 
Data Collection: Standardized across 
sites 
Nonparticipation bias: Systematic error 
related to participants; participants with 
certain characteristic might drop out 
 
Attrition: Participants will continue as 
they remain in health care system.  
Statistical regression: Not necessary 
Data Collection: Varied by different 
providers 
Nonparticipation bias: systematic error 
related with healthcare system itself, 
participants 




Participants must agree to join; 
participation rate declines overtime 
Participants must be enrolled in the 
health care system 
 
 
Chapter 2.11: Current status of EHRs in T2DM Clinical Research  
 
Currently, there are 114 articles which utilize EHRs for T2DM research[139]. In those articles, the 
research topics can be grouped into following fields: epidemiology, prevention, susceptibility, 
diagnosis, prognosis, complications, medication treatment, medication side effect, non-pharmacy 
intervention, and insurance-based service delivery. The major reported barriers are missing values 
(e.g., no related information of glucose values, limited information about complications, and death 
reasons). Other major barriers are limited information on medication compliance, misclassification 
of diabetes, data extraction problems of unstructured data, lacking longitudinal data in certain 
EHRs, and fragmentation of patient information.  
 
Chapter 2.12: Current Progress of Temporal Representation in the EHR 
 
There is a variety of temporal information incorporated in the EHR. However, how to represent 
the temporal information can still be a challenge. EHRs keep all available patients’ information in 
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each visit. For each visit, EHRs store information including multiple medical concepts such as 
diagnosis, medication, and procedure codes. The variation of each visit including the changing 
records of diagnosis, medications, and lab results implies a temporal pattern which can be used to 
understand patients' health condition over time. For example, the variation of the results of HbA1c 
over several time points can deliver more information for machine learning algorithms to build a 
model for early detection. 
 
The records of patient’s visits provided two major relational information types, namely sequential 
order of visits and co-occurrence of the codes within each visit. The sequential order of visits might 
provide the progression of health conditions. Several papers utilized the sequential order of visits 
for training the representation of medical concepts. The medical concepts include diagnosis, 
medications, laboratories, vital signs, and procedures. The researchers used a high-dimensional 
representation for indicating each medical concept. Those high-dimensional representations were 
based on the sequential order of visits which have carried temporal information. Several methods 
can be used to represent this temporal information. This dissertation will start with the most 
popular method "word2vector (w2v)".  
 
Word2vector (w2v) has two major methods.  One is the "Skip-Gram" model and the other is 
"Continuous Bag of Words (CBOW).” Both models were types of word2vector models. The skip-
gram model looped on the word of each sentence and tried to use the current word to predict its 
neighbors. In contrast, CBOW model used the current word's neighbors to predict the current word. 
Both models used a parameter to determine how many words should be considered. This parameter 
was called "window size". Several papers used "Skip-Gram" model to train medical temporal 
concepts. One of the papers used several data sources including medical journals (OHSUMED 
dataset), medical claims data, and medical narratives for training the concepts[140]. Medical 
claims data, and medical narratives suffered duplications which might affect the temporal 
distributional pattern in an uninformative way. They also assumed the ordering of the events which 
happened in a short period of time may not be important. By these two assumptions, they 
partitioned the medical events of medical claims data, and medical narratives into several time 
intervals, removed duplications within each period, and put the data into the "Skip-Gram" model. 
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The previous example is a type of consideration of time. Adler Perotte in his paper "Parameterizing 
time in electronic health record studies" proposed the EHR has two types of time[141]. One is 
"clock time", and the other is "sequence time". People measured medical concepts (e.g. HbA1c) 
in "clock time" under the time units such as seconds, days, months, or years. "Sequence time", in 
contrast, measures medical concepts (e.g. HbA1c) between the members of any pair. The members 
of any pair might be two clinical visits or two laboratory orders of the same laboratory. In their 
research, they compared the variance of median absolute value as an outcome of four medical 
laboratories including creatinine, glucose, sodium, and potassium over time. For the predictors, 
they measured the variance of the previous four medical laboratories within two consecutive 
measurements of each patient under "clock time" and " sequence time" and spread the variance 
into 10 bins. Under this experiment, they found "sequence time" produced the most stationary 
series. In time series analysis, stationary means the variance is consistent over time and the 
abnormal variance is easy to identify. 
 
Continuing from the previously mentioned two types of time, Edward Choi and colleagues 
developed two types of medical concepts representation. One is Med2Vec model[142], and the 
other is GRAM model[143]. In Med2Vec model, they used binary representation to represent 
medical concepts in each visit as a binary vector. This binary vector went into multiple layer 
perceptron (MLP) to get a condensed vector and used the "Skip-Gram" model to optimize it. In 
Med2Vec model, they indicated this method not only considered the sequential information 
(sequence time) but also encompassed the concurrence information within each visit. In GRAM 
model, they incorporated ontology information into training temporal medical concepts. The 
ontology information utilized in this research is ICD-9-CM/PCS, which has a parent-child 
hierarchical structure. They combined ontology information with the Glove[144] method to 
improve the performance of the prediction model by more than ten percent. 
 
Besides using previous methods, some researchers started to apply Convolutional Neural Network 
(CNN) to generate the temporal representation of medical concepts. Phuoc Nguyen and colleagues 
developed a deep learning model called "Deepr"[145]. This model combined "w2v" and CNN to 
create a new model for learning temporal medical concepts. The structure of this model separated 
the timeline of EHRs into several intervals and aggregated all medical information into those 
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intervals. The medical concepts in each interval will get high-dimension representation from 
"w2v". CNN processed the representation of all medical concepts within each period and applied 
"max-pooling" method to summarize all information based on all intervals. "Deepr" can generate 
a more accurate pattern of readmission compared with traditional methods. 
 
Recently unsupervised machine learning methods applied to EHRs had been under-developed. 
"Deep Patient " is a good example to illustrate how to apply a stack of denoising autoencoders to 
learn temporal medical concepts[146]. This research used 704,582 patients with 41,072 clinical 
descriptors as a training dataset. The clinical descriptions encompassed diagnosis codes, 
medications, lab tests, vital signs, and clinical notes. All clinical notes used LDA model to capture 
300 topics. Eighty-one thousand, two hundred fourteen, (81,214) patients were used to validate 
and test the model. This research indicated that the representation from "Deep Patient" achieved 
higher accuracy compared with representations generated by K-means, PCA, and GMM. Takayuki 
Katsuki and colleagues used Stacked Convolutional Autoencoder (SCA) to extract interpretable 
temporal medical concepts representation[147]. They focused on lab tests of diabetic nephropathy 
patients. A 2-D matrix was used to describe each patient. One dimension of this 2-D matrix was 
time, and the other is lab tests. They found several temporal medical concepts associated with 
diabetic nephropathy, such as CRP, EGFR, and amylase, had some interesting temporal patterns.  
 
Attention mechanism is an emerging field for developing temporal medical concept 
representations. The attention mechanism can capture global information rather than depend on 
the information provided by the hidden state for better prediction. Yuan and colleagues utilized 
this mechanism combined with "CBOW" to generate a model called Medical Concept Embedding 
with Time-Aware Attention[148]. In this paper, they categorized all medical diagnosis code into 
the following three types 1) Stable influence, 2) Peak influence, and 3) Sequela influence. Laura 
and colleagues considered consequent visits had some temporal correlations within them and 
attention mechanism can capture those temporal correlations[149]. The researchers aggregated all 
EHR's medical concepts into several continuous periods and utilized the attention mechanism to 
seize that information and processed that information by RNN and additional attention mechanism. 
All of EHR's medical concepts were represented by "word2vector". 
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The previously mentioned works mainly focused on medical concepts including diagnosis codes, 
medications, and others. The results of those medical concepts were categorized into binary values 
or categorical values rather than continuous values. For monitoring the trends of lab tests or vital 
signs in real-time, this is not an appropriate approach. One of the major challenges is missing 
values due to policies or data collection periods. Cara O’Brien and colleagues found a Gaussian 
processes/RNN model which can handle missing value and can perform imputation based on 
Gaussian distribution[150]. They compared their model with RF, LASSO model and traditional 
sepsis prediction model and found Gaussian processes/RNN model had a better performance. 
Based on the same work, Benjamin M. Marlin proposed the use of Radial Basis Function Network 
to replace Gaussian processes and found the model performance was better than others[151]. Other 
researchers proposed the use of "Mixtures of Expected Gaussian Kernels" to solve continuous 
variables with irregular sampling time and the high proportion of sparsity[152]. 
 
Chapter 2.14: Current Progress of Deep Learning Models in the EHR 
 
From 2012 to 2017, the annual number of deep learning papers was growing[153]. Those papers 
covered topics ranging from concept representation, phenotyping, information extraction, and 
prediction, to deidentification. The methods utilized by those papers included RNN, CNN, 
autoencoder, Boltzmann Machine, Deep Belief Network (DBN), and Multilayer Perceptron. In 
this section, I focus on the prediction models.  
 
Based on the prediction outcome type, we can categorize all papers into two categories, one is 
static outcome prediction and the other is temporal outcome prediction. Static outcome prediction 
is predicting a specific outcome without considering temporal constraints. The medical concept 
vectors generated by "skip-gram" had been demonstrated with better performance for predicting 
health failure in SVM, MLP, logistic regression, and KNN[154]. Besides "skip-gram", DBN can 
be trained with medical concept vectors and present better precision when compared with SVM, 
or RF[155]. Stacked Sparse Auto Encoder classifier and Stacked Restricted Boltzmann Machine 
classifier combining with word2vector model, TF-IDF, and PCA model also demonstrated better 
performance in predicting healthcare-associated infections[156]. 
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Temporal outcome prediction can predict the outcome, or onset within a specified time interval, 
or make a prediction based on time series data. Most temporal outcome prediction models were 
based on RNN.  Lipton and colleagues used LSTM networks to predict multiple labels prediction. 
In the final step, this network only predicted one of 128 diagnosis codes at the final output but this 
network also used target replication at each timestep for handling the less-common diagnosis codes 
as a regulation[157]. Doctor AI was another example which used one, or multiple RNN layers 
used hidden states, to predict the diagnosis codes and the medication codes by Softmax function 
and to predict the time duration between two visits by ReLU function[158]. RETAIN advanced 
this idea and incorporated the attention mechanism for building the interpretable model[159]. 
Dipole model was Bi-LSTM RNN model combining with several different types of attention 
mechanisms including 1) location-based attention, 2) general based attention, 3) concatenation-
based attention[160]. DeepCare created two separate vectors per patient admission. One is for 
diagnosis codes and the other is for intervention codes. This model also considered time decay 
effects after max-pooling layer[161]. 
 
CNN is a famous deep learning model which is widely applied to medical image 
classification[162], abnormal EGG detection[163], medical concept embedding and 
classification[164], and prediction models. The following is the review of EHR prediction models 
based on CNN. Multi-layer convolutional neural networks is a deep learning method widely 
applied to text mining, image classification, and other fields. Recently, this method was combined 
with word2vector to build an EHR prediction model which outperformed  other traditional 
machine learning methods[165]. CNN was also used to predict heart failure, kidney failure, and 
stroke by different lengths of kernel to capture temporal information within a time window. The 
performance, however, lagged behind Bi-LSTM[166]. Word2Vector, grouped code Vector, and 
binary vector combined with CNN respectively had also been tested for the early detection of  heart 
failure [167]. MATCH-Net is a model which combines CNN and survival analysis. The CNN part 
extracts temporal information, overcomes the missing value effects, and generates the risk score 
at each time point[168].  
 
Beyond RNN and CNN, other deep learning algorithms have been used to build prediction models 
based on EHR data. The first example is Hidden Markov Models (HMM). HMM had been 
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implemented to predict the progress of COPD[169]. Another example is using HMM to model the 
treatment pathways under real patient data[170].  Depth Belief Network (DBN) is another wildly 
used deep learning model. DBN started to build a model for forecasting cardiovascular disease 
from attributes extracted from the EHR including age, gender, serum cholesterol, ST wave 
depression, and other features[171]. Multiple DBNs are used for processing different information 
inputs and generating predictions from each source. The outputs from DBNs can be further 
processed by Dempster-Shafer theory to predict the stage of prostate cancer [172]. Generative 
adversarial network (GAN) is a semi-supervised deep learning method which can train a model by 
real example and GAN generated examples. The final model should distinguish the real example 
and GAN generated examples in the end. Most GAN models are based on images and ehrGAN is 
the first model of GAN based on EHR[173]. In ehrGAN model, the research found some diagnosis 
codes such as hypothyroidism, hypertension, and other variables related with the previous two 
conditions prevalent in the dataset which might imply those diagnosis codes are associated with 
DM. The GAN models based on EHR had a limitation of missing values. For overcoming this 
problem an autoencoder had been introduced for imputation, and the GAN learned the dataset with 
imputation[174]. 
 
Graph Augmented Memory Networks is a state of the art deep learning method which can 
incorporate domain knowledge and EHR together and recommend the best strategy of 
prescriptions[175]. The original idea came from graph CNN which can generate embedding for a 
node base on nearby nodes. This paper used the characteristic to generate a graph to represent 
drug-drug interaction[176]. 
 
Chapter 2.15: The Implications of Temporal Representation for T2DM in the EHR  
 
Generally speaking, EHRs hold an amount of temporal information for mining the progress of 
diseases. The progress of a disease can be summarized as a phenotype for further research. Current 
EHR-based prediction models focus on clinical events likelihood either within an unspecified time 
period (i.e., at some unknown future point) or with a fixed period (i.e., in the next two years).  
Those models consider utilizing the whole information or using the latest information. They may 
or may not explain how the temporal information affects the model. Because the temporal 
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information can indicate, to some extent, the variance of some variables or lasting some chronic 
conditions might be useful for further research. 
Different types of temporal representation can assist machine learning algorithms to learn different 
types information from the data. Understanding how different types of temporal representation 
affects machine learning algorithms can give us hints how to utilize EHRs in the future. For 
achieving this goal, this dissertation will separate this goal into three specific aims.  
Aim 1. Running the three approaches 1) Non-Temporal, 2) Interval-temporal and 3) Continuous-
temporal representation on the University of Texas Physician’s development dataset (UTP dataset). 
Aim 2. Running the three approaches 1) Non-Temporal, 2) Interval-temporal and 3) Continuous-
temporal representation on Cerner Health Facts validation dataset (CHF dataset). 




























Chapter 3: The Comparison of Different Types of Temporal 
Representation over Development and Validation Dataset 
 
 
Chapter 3.0: Overview  
 
This study utilizes two datasets: the UT Physician (UTP) dataset and Cerner Health Facts (CHF). 
The datasets are summarized using descriptive statistics. In order to capture and apply temporal 
information, three types of temporal representation will be developed and applied to this research, 
encompassing non-temporal representation, interval representation, and continuous representation. 
I will compare the difference between the two datasets, list the performance of the model over two 
datasets, and discuss the results.  
Chapter 3.1: Running the Three Approaches on UTP Dataset  
Chapter 3.1.0: Introduction of UTP 
 
The UT Physician dataset encompasses several clinical information inputs such as Allscripts, 
Centricity, and axiUm. Allscripts is currently the EHR system for the UT Physician Faculty 
Practice, which includes records of clinical notes, diagnoses, medications, results of laboratory 
tests, and vital signs. Centricity is a GE billing system that provides information related to claims. 
axiUm is an EHR system currently implemented in the UT Dental School. This research primarily 
uses the information from Allscripts but excludes clinical notes. The transition to a new diagnostic 
coding system might affect the consistent meaning for a given condition. To avoid this issue, this 
research only utilized the data before Oct/01/2015, which was the official date of the ICD-10-
CM/PCS implementation. Allscripts before Oct/01/2015 only had 820,217 patients who had at 
least one datum. In those patients, 37,907 patients were T2DM patients, 723,634 were non-T2DM 
patients, and others were T1DM patients or prediabetes patients. One challenge is that some 
patients did not routinely visit the primary care clinics, resulting in missing information in the 
EHR. For those patients, we cannot make reliable predictions. In this research, we excluded the 
patients who had fewer than ten office visits between Jan/01/2000 and Oct/01/2015. The qualified 
patients were 121,621 patients. Of those patients, 9,579 were T2DM patients and 112,052 were 
non-T2DM patients 
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Chapter 3.1.1: The Demographic Information of UTP Datasets 
The following sections will illustrate the demographic constitution, the frequency of diagnosis, 
medications, laboratory, and vital signs. This section will also provide the proportion of the 
missing values of some essential measurements such as height, weight, and blood pressure of both 
datasets. The first sections are the summary of demographic information of the two datasets. The 
demographic information includes race, gender, and age when enrolled in this dataset. 
Chapter 3.1.1.1: The Information of Demographic – UTP 
 
Figure 1. The Summary of Demographic Features - UTP 
 
Fig1.A is the race proportion of UTP dataset, the figure excluded the race below 1% of the 
dataset. Fig1.B is the gender proportion of UTP dataset, the figure excluded the gender below 













Chapter 3.1.1.2: The Information of Years of Data – UTP 
 
Figure 2. The Summary of Proportion of Patient with Datum Over Years - UTP 
 
From figure 2, the number of patients with available data drops as you go back through the years. 
Less than half of the patients had more than five years of data in the UTP dataset. This is the 
limitation for building a long-term prediction model.  
 
Chapter 3.1.2: Methods 
 
Handling EHRs, which involve complex datasets, includes a number of issues such as patients 
returning irregularly, data representation, determining the final status of patients, defining 
experiment schemes, and analysis methods. The analysis methods in this section focus on several 
machine-learning algorithms, including deep-learning methods.  
 
Chapter 3.1.2.1: Chronic Condition Indicators Imputation 
 
For solving the problem in which patients did not return regularly, I introduced the Chronic 
Condition Indicator (CCI) to perform condition imputation. CCI is maintained by The Agency for 
Healthcare Research and Quality (AHRQ)[177]. CCI provides an approach for researchers to 
categorize approximately 14,000 ICD-9-CM diagnosis codes into two major categories: chronic 
and not-chronic conditions. CCI also classifies chronic conditions into 18 body system categories 
to imply which system is affected by a chronic condition. The definition of a chronic condition 
used by the CCI is a condition which can last 12 months or longer and meets one or both of the 




























Proportion of pateint with datum over years
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and (b) it results in the need for ongoing intervention with medical products, services, and special 
equipment. Based on this definition, I assumed the patients with a chronic condition would 
continue having this condition until the next visit. More details can be found in Figure 3. In Figure 
3, a patient received the hypertension diagnosis code in the first and the third year but did not 
provide any information in the second year. This will be an information gap in the second year. 
With the assistance of CCI, we can still assume this patient had a chronic condition even though 
we did not have any information. I did not adapt using the previous codes because we did not know 
the exact status at that time point. 
Figure 3. The Illustration of CCI Imputation 
 
Chapter 3.1.2.2: Data Value Representation 
 
This research focused on using structured data rather than unstructured data. The structured data 
encompassed records of diagnosis, medications, laboratory, vital signs, and demographic 
information. For diagnosis, medication, and demographic information, I used binary representation 
(yes/no) to represent this information. For laboratory and vital sign information, I used data 
binning and min-max normalization to present the information. The value of records of each 
variable was in six categories from two standard deviations below the average to above two 
standard deviations above the average. All records of the variable determine the average of each 
variable. I constrained the range of height and weight to prevent the use of questionable data. The 





Chapter 3.1.2.3:  The Algorithm to Distinguish T2DM and Non-T2DM Patients  
 
Before building the temporal representation, I built an algorithm to differentiate T2DM patients 
and non-T2DM patients. The T2DM patients should satisfy one of the three criteria 1) a T2DM 
diagnosis codes; 2) use of T2DM medications except for metformin, or 3) using metformin 
combined with a record of abnormal plasma glucose. Non-T2DM patients should meet the 
following three criteria 1) patients without any DM and DM-related diagnosis codes; 2) patients 
without DM medications; and 3) patients without records of abnormal plasma glucose. The criteria 
for glucose measurement followed the ADA guide. Both T2DM and non-T2DM patients should 
not receive any T1DM diagnosis codes. Detail of the diabetes criteria is listed in Table 7. 
 
Table 7. The data element of diabetes criteria 




T1DM Diagnosis Codes: 250.x1,250.x3 
T2DM Diagnosis Codes: 250.x0,250.x2 
DM related Diagnosis Codes: 277.7,648.0x,648.8x,791.5,790.2,790.29,790.21,790.22 
DM meds T1DM Medications:  
Insulin, pramlintide, symlin 
T2DM Medications:  
acetohexamide, tolazamide, chlorpropamide, glipizide, gluburide, glimepiride, 
repaglinide, nateglinide, metformin, rosiglitazone, pioglitazone, troglitazone, acarbose, 
miglitol, sitagliptin, exenatide, dymelor,tolinase, diabinese, Glucotrol, Glucotrol- XL, 
micronase, glynase, diabeta,amaryl, prandin,starlix, Glucophage, Avandia, ACTOS, 











Chapter 3.1.2.4: Introduction of Each Types of Temporal Representation 
When we spread patient data into the timeline, the data points of a patient's data are not evenly 
distributed. Besides, when the data points are closer to the date of diagnosis, the data points might 
be more important than the ones further from the date of diagnosis. Based on this assumption, this 
research set up three types of temporal representation. A simple illustration of three types of 
temporal representation is shown in Figure 4. In the figure, the non-temporal representation uses 
the latest time point, which indicates the nearest information of a feature related to the event. An 
interval-temporal representation utilizes the full information but aggregates the information into 
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each interval. The continuous-temporal representation utilizes not only the full information but 
also the trend presenting in the dataset.  
Figure 4. The Illustration of Three Types of Temporal Representations 
                                                   
The table 8 is an example of a non-temporal representation. In the non-temporal representation, 
each row is a patient, and each column is a feature of a patient. The value of each cell is the latest 
information about this feature of a patient. The drawbacks of non-temporal representation are that 
EHR data might be spotty and inconsistent and lack the concept of time. For example, the diagnosis 
of hypertension was one month ago, and the diagnosis of influenza was one year ago. Were both 
events equally crucial for the prognostic prediction model? 
 
Table 8.The example of Non-Temporal Representation 
Patient 401.1 Prozac HDL Systolic Class 
A Y Y 30 140 T2DM 
B N N 40 110 Non-T2DM 
C N Y 44 145 T2DM 
D Y Y 45 130 Non-T2DM 
E Y N 20 130 T2DM 
 
Interval-temporal representation divides the complete information into several equal-length 
periods like one month, two months, one year, two years, and others. Table 9 is the example of 
interval-temporal representation. The interval-temporal representation can be considered an 
extension of non-temporal representation but can incorporate some concepts of time. Compared 
with non-temporal representation, interval representation can use more columns to represent the 
same variables at different time points. One of the drawbacks of this kind of representation is too 
much granularity. The curse of dimensions, a situation with too many variables but without enough 
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examples, can occur with interval representation. The curse of dimensions affects the performance 
of machine learning algorithms. Another drawback is missing values. Unlike non-temporal 
representation, the interval-temporal representation will present several time-points, some lacking 
information. Although the curse of dimensions remains a challenge, we can use feature selection 
to reduce irrelevant variables to avoid the curse of dimensions. For missing values, I can use 
imputation to mitigate the effects of this problem. The most important question is whether interval 
representation lacks information about the order of events. This means that machine learning 
cannot discern which event happened first and which event happened next. This challenge, 
however, cannot be solved by interval representation. I propose to develop continuous 
representation to compensate for this deficit. 
 
Table 9. The example of Interval-Temporal Representation 
 
Compared to interval-temporal representation, which treats every event on a timeline discretely, 
continuous-temporal representation treats every variable including diagnosis, medications, lab 
results, and vital signs continuously in the timeline. The continuous-temporal representation is a 
regression function that can predict future points continuously based on currently available data 
points (Figure 5). Those predicted future data points are expected to improve the performance of 
the prognostic prediction model. Continuous-temporal representation is the best temporal 
representation and can be generalized to other types of chronic conditions. The continuous-
temporal representation, however, has several disadvantages including unknown methods to 
accurately estimate variables, mitigate confounder effects, and demonstrate previous data points 




Patient Month 1 Month 2 Class  
401.1 Prozac HDL Systolic 401.1 Prozac HDL Systolic  
A Y Y 30 120 Y Y 30 140 T2DM 
B N N 50 110 N N 40 110 Non-T2DM 
C N N 30 120 N Y 44 145 T2DM 
D N Y 42 140 Y N 45 130 Non-T2DM 
E Y N 25 120 N N 20 130 T2DM 
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Figure 5. The Illustration of Continuous-Temporal Representation 
 
The previously mentioned disadvantages of continuous-temporal representation can be solved with 
deep learning. Deep learning is a linear algebra-based machine-learning method that can 
incorporate categorical and numerical data to generate a vector for further learning. Based on this, 
the continuous-temporal representation will use deep-learning methods to achieve such as RNN. 
Chapter 3.1.2.5: The Experimental Schemes 
There are two experimental designs in this research. The first is the cutting-points scheme, and the 
second is the random-split scheme. The cutting-points scheme is illustrated in Figure 6. In the 
figure, the blue part is the data we used to build the prediction model, and the red part is the data 
discarded for developing a time gap. If we want to predict four different time points, we need to 
build four models. 




Figure 7. The Illustration of the limitation of Cutting Points Scheme 
 
There are several limitations for this experiment design. The primary limitation is an inconsistent 
number of patients. There were fewer patients for building earlier identification models. The 
estimated risks of cutting design models are decreasing and variations are increasing. The detail is 
presented in Figure 7.  
In long-term estimation for a chronic condition, this is a problem for building a prevention plan. 
The other problem is data sparsity, which might affect the results of outputs. This is why we need 
another training design, called the “random-split design.” The random-split scheme (Figure 8) is 
unlike the cutting-point design, which is forced to use data before specific time points. The random 
design splits patient data into a portion for building models (the blue part) and a piece for creating 
a time gap (the red part). This design, combined with a deep learning model, can make some 
projections (dashed line) in the future even though we do not have data after specific time points. 
Figure 8. The Illustration of the Random Splits Scheme 
 
In this research, non-temporal representations and interval-temporal representations used both 
















Chapter 3.1.2.6: Introduction of Machine Learning Methods 
 
Several machine learning algorithms were used to evaluate the performance of the three types of 
temporal representations. In the evaluation of non-temporal representations and interval-temporal 
representations, several different types of machine learning algorithms—including linear models, 
ensemble methods, support vector machine, decision trees, multiple layer perceptions, and 
Bayesian methods—were applied to this research.  This research primarily tested logistic 
regression, Lasso, Elastic Net, and multi-task linear models. Ensemble methods encompassed 
random forest and AdaBoost. The equation of each algorithm will be listed in Table 10. AUC, 
precision, recall, and F1 measure are applied to evaluate the performance of each machine learning 
algorithm. 
 
Table 10. The Equation for Each Machine Learning Algorithm 
Methods Algorithm 






Support vector machine 
 
 
The continuous-temporal representation used Recurrent Neural Network (RNN) as a machine 
learning method to learn the progress of patient history. RNN can process the information within 
a period or information of a single visit as a stage and transfer the information from this stage to 
the next step. RNN also outputs the outcome of each stage for further prediction. The process is 
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We analyze the stochastic average gradient (SAG) method for optimizing the sum of a finite
number of smooth convex functions. Like stochastic gradient (SG) methods, the SAG method’s
iteration cost is independent of the number of terms in the sum. However, by incorporating a
memory of previous gradient values the SAG method achieves a faster convergence rate than
black-box SG methods. The convergence rate is improved from O(1/
p
k) to O(1/k) in general,
and when the sum is strongly-convex the conv rgence rate is improved from the sub-linear
O(1/k) to a linear convergence rate of the form O(⇢
k
) for ⇢ < 1. Further, in many cases the
convergence rate of the new method is also faster than black-box deterministic gradient methods,
in terms of the number of gradient evaluations. This extends our earlier work [Le Roux et al.,
2012], which only lead to a faster rate for well-conditioned strongly-convex problems. Numerical
experiments indicate that the new algorithm often dramatically outperforms existing SG and
deterministic gradient methods, and that the performance may be further improved through
the use of non-uniform sampling strategies.
1 Introduction
A plethora of the optimiz tion probl ms arising in p actice involve computing a minim zer of a









where the ai 2 Rp and bi 2 R are the data samples associated with a regression problem. Another







log(1 + exp( bia>i x)),
where the ai 2 Rp and bi 2 { 1, 1} are the data samples associated with a binary classification
problem. A key challenge arising in modern applications is that the number of data points n
(also known as training examples) can be extremely large, while there is often a large amount of
redundancy between examples. The most wildly successful class of algorithms for taking advantage of
1
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Assuming s ≥ 0 , Chebychev’s inequality gives
        PE* ≤ var(mr)/s2               (4)
A more revealing expression for the variance of mr  is derived in the following:
Let
ĵ (X,Y )=argmax j≠Y PΘ (h(X,Θ)= j)
so
mr(X,Y ) = PΘ (h(X,Θ)=Y )−PΘ (h(X,Θ)= ĵ (X,Y ))
    = EΘ[ I(h(X,Θ)=Y )− I(h(X,Θ)= ĵ (X,Y ))].
Definition 2.2  The raw margin function is
rmg(Θ,X,Y )= I(h(X,Θ)=Y )− I(h(X,Θ)= ĵ (X,Y )).
Thus,  mr(X,Y) is the expectation of rmg(Θ,X,Y) with respect to Θ .  For any
function f  the identity
[EΘ f (Θ)]
2 = EΘ,Θ' f (Θ) f (Θ' )
holds where Θ,Θ'  are independent with the same distribution, implying that
mr(X,Y )2 = EΘ,Θ'rmg(Θ,X,Y )rmg(Θ' ,X,Y )      (5)
Using  (5) gives
     var(mr)=EΘ,Θ' (covX,Y rmg(Θ,X,Y )rmg(Θ' ,X,Y ))
        = EΘ,Θ' (ρ(Θ,Θ' )sd(Θ)sd(Θ' ))       (6)
where  ρ(Θ,Θ' ) is the correlation between rmg(Θ,X,Y )and rmg(Θ' ,X,Y ) holding
Θ,Θ'  fixed and sd(Θ)  is the standard deviation of rmg(Θ,X,Y )  holding  Θ  fixed.
Then,
var(mr) = ρ (EΘsd(Θ))
2       (7)
                                                   ≤ ρEΘ var(Θ)
where  ρ  is the mean value of the correlation; that is,
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Figure 9. The Illustration of the Recurrent Neural Network 
 
Figure 10. The Illustration of the LSTM cell and GRU Cell 
 
 
Each unit of RNN used to process information is called a cell. There are two major types of cells. 
One is called an LSTM cell and the other is a GRU cell. The equation and process of LSTM and 
GRU cells are the following. The LSTM cell had three gates and two states. The three gates are 
the input gate, output gate, and forget gate. The forget gate determines how much information from 
the previous stage should be discarded, the input gate updates the newest information, and the 
output gate sends the information to the next LSTM cell. There are two states of the LSTM cell; 
one is the cell state and the other is the hidden state. The cell state is across the whole LSTM-RNN, 
and the hidden state is just within each LSTM cell and transfers to the next LSTM cell. The cell 
state can be considered a long-term memory, and the hidden state can be seen as short-term 
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memory. The GRU cell combined the input gate and the forget gate together to form an update 
gate. Besides, the cell state combines with the hidden state to be simplified as a hidden state. Thus, 
GRU cell is not like an LSTM cell, which has long-term and short-term memory. The equation of 
LSTM cell and GRU cell is listed in Table 11. 
 
Table 11. The illustration of the equation of LSTM cell and GRU cell 
 
RNN has the advantage of utilizing the previous information for estimating the current risks of 
disease. The limitation is that RNN needs current information combined with previous information 
to estimate present risks. In clinical reality, we not only need current risks but also need to project 
future risks, especially for prevention. 
To overcome this limitation, the seq2seq model was proposed. The seq2seq model originally was 
applied to machine translation, which learned from the information in the encoder then 
continuously generated outputs with no data inputs. This research used this advantage to combine 
random splits to generate a sequential risk estimation for each patient. The illustration is found in 
Figure 11. 
Figure 11. The Illustration of the seq2seq Model 
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Chapter 3.1.3: Findings 
 
In this section, I will summarize the finding of the UTP dataset, the performance of the 
conventional model, non-temporal representation, interval-temporal representation, and 
continuous-temporal representation.  
 
Chapter 3.1.3.1: The Summary of the UTP dataset 
In Table 12, I compare the following variables that might affect the performance. For T2DM and 
non-T2DM patients, there were no differences between enrolling years, gender, and systolic and 
diastolic pressure. The only differences were in age and weight. The T2DM patients were more 
elderly and weighed more. 
 
Table 12. The Summary of UTP Dataset 
UT Physician T2DM (Mean/ S.D.) Non-T2DM (Mean/ S.D.) 
Enrolling years 4.423/5.759 year 5.683/2.674 year 
Enrolling age 56.13/16.11 year 44.35/20.79 year 
Gender Ratio Female: 57.8 % /Male: 42.2% Female: 59.7 % /Male: 40.3% 
Weight 90.2/27.4 Kg 59.8/33.7 Kg 
Systolic 131.23/20.0 mmHg 122.83/23.3 mmHg 
Diastolic 78.7/11.6 mmHg 74.7 /15.1 mmHg 
 
Chapter 3.1.3.2: The Summary of Top Variables over Different Data Types 
 
In the previous section, I introduced some differences that might affect the performance of the 
prediction model. For more detail, I present the difference between T2DM and non-T2DM patients 
in the UTP dataset. In this section, I will present the differences in the diagnoses, medications, 
labs, chronic conditions, and vital signs. The T2DM patients received more diagnoses in 
unspecified essential hypertension, shortness of breath, pulmonary collapse, chest pain, abnormal 
pain, conduction disorder or cardiac dysrhythmia, and asthma. Sleep disorder and osteoporosis had 
a few more T2DM patients than non-T2DM patients. A more interesting phenomenon is that non-
T2DM patients generally had more records of labs and vital signs than T2DM patients. 
The essential information such as BMI, systolic blood pressure, diastolic blood pressure is not 
complete for everyone. The information, generally speaking, was the essential factor in most of 
the prediction models. This might introduce some strong limitations in applying those prediction 
models to the EHR system.  
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In addition, there were no differences among the drugs that were prescribed to T2DM and non-
T2DM patients. All high-frequency drugs were aspirin. This situation might be due to UTP being 
a primary care hospital. As such, all relevant information is in Figure 12. 
Figure 12. The Summary of Top Information Rich Variables - UTP 
 
 
Chapter 3.1.3.3: The Conventional Model Performance – UTP 
 
For testing the performance of three types of proposed temporal representations, the conventional 
model proposed a baseline for comparison. The conventional model is based on the traditional 
variables for predicting Type 2 diabetes. Those variables include BMI, systolic blood pressure, 
diastolic blood pressure, triglycerides, fasting plasma glucose, HbA1c, records of hypertension, 
records of hyperlipidemia, records of obesity, age, gender, and race. Age was recorded by 
comparing the date of birth to the last time point information was recorded for the patient. The 
absence or presence of hypertension, hyperlipidemia, and obesity of a patient was based on CCI 
and constituted binary variables. Other patient variables came from the last records of those 
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the same comparing test scheme, this section and the next section used the cutting-points scheme. 
Table 13 presented the T2DM and non-T2DM patients at each time point.  
In Figure 13, I listed all the variables that show the percentage of patients with values at that time 
point. More than sixty percent of patients had a record of systolic and diastolic blood pressure, and 
the percentage decreased over the years. The BMI decreased more sharply, which is the most 
important variable to estimate the risks of developing T2DM. Other variables stayed constant over 
the years.  
 
Table 13. The Summary of Patient Number at Cutting Points Scheme-UTP 
Cutting time points  T2DM  Non-T2DM  
One year  5,232  83,710  
Two years 4,049  64,565  
Three years 3,232  49,892  
Four years 2,637  40,297  
Five years 2,117  32,856  
 
In the figure 13, I listed the all variables which how many percent of patients with values at that 
time point. More than sixty percent patients had record of systolic and diastolic blood pressure and 
the percentage decreased over years. The BMI decreased more sharply which is the most important 
variable to estimate the risks of developing T2DM. Other variables stayed constant over years.  
Figure 13. The Proportion of Patients with Records Over Years in Conventional Model-
UTP 
 
In Table 14, I listed the performance of the conventional model at each time point. The 
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each patient. With the current available data, the results implied that the conventional model cannot 
provide any reliable information to estimate future risks.  
Table 14. The Performance of Conventional Model at Cutting Points Scheme-UTP 
Cutting time points  AUC ACC  
One year  0.481  0.580  
Two years 0.517 0.553 
Three years 0.494 0.547 
Four years 0.482 0.497 
Five years 0.519 0.534  
 
Chapter 3.1.3.4: Non-temporal and Temporal Representations Performance – UTP 
In the following section, I presented the performance of three types of temporal representation. In 
Figure 14, the model used all available information before the cutting timepoints and tested the 
non-temporal representation. The earlier cutting timepoint indicates less information for building 
a prediction model and presented a poor performance. In all the testing of machine learning 
algorithms, the top three machine learning algorithms with the best results were random forest, 
perceptron, and logistic regression. For interval-temporal representation, the top three machine 
learning algorithms were logistic regression, perceptron, and random forest (Figure 15).  
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 44 
Figure 15. The Results of Interval-Temporal Representation - UTP 
 
Chapter 3.1.3.5: Random Split Model Performance – UTP 
 
In this part, I will introduce the performance of the random split scheme. The first part is the basic 
information for the experiment performed under the random split scheme. In Table 15, we found  
the number of case-control in the full dataset and above three years of data in the encoder, which 
represents the more comprehensive information in the training dataset.  
Table 15. The Basic Information of Random Split Scheme - UTP 
UTP Dataset 
(All Patients) 











Non-T2DM  85,960 (3.32 /2.81)  (3.32/2.82)  (40.0/23.9) 




Three Years of 
History in 
Encoder) 











Non-T2DM  40,017 (5.61 /2.61)  (3.58/2.60)  (40/23.9) 
T2DM 2,684 (5.13/2.24) (3.16/2.28) (55.0/16.3) 
 
In Table 16, I listed the performance of non-temporal representation and the performance of 
Random Split by using all patients and using patients with at least three years of data in the encoder. 
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than using patients with fewer years of information in the encoder. The attention mechanism 
seemed to have no effect on the performance in our experiment. 
 
Table 16. The Performance of Random Split Scheme - UTP 
Table 16.A: Non-Temporal UTP 
Method AUC 
Logistic Regression  0.648 
Random Forest 0.639 
 
Table 16.B: Random Split  UTP_all 
Method AUC 
RETAIN  0.718 
RNN  0.704 
seq2seq  0.823 
seq2seq with attention wrapper in 
encoder 
0.823 




Table 16.C: Random Split   UTP_Encoder over Three Years 
Method AUC 
RETAIN  0.732 
RNN  0.720 
seq2seq  0.831 
seq2seq with attention wrapper in 
encoder 
0.830 




Table 17 uses Mean Absolute Error (MAE )to estimate the performance of early detection of 
T2DM. From this perspective, the MAE of T2DM patients should be much higher than that of 
non-T2DM patients. The results met my expectations but using patients with more information in 
the encoder did not improve the performance. Thus, the attention mechanism makes no difference 







Table 17. The MAE of Random Split Scheme - UTP 
Model MAE (T2DM group) MAE (Non-T2DM group) 
Continuous: UTP_all 
seq2seq  0.278 0.052 
seq2seq with attention 
wrapper in encoder 
0.283 0.074 
seq2seq with attention 
wrapper in decoder 
0.281 0.07 
Continuous: UTP_encoder_year over three years 
seq2seq  0.280 0.051 
seq2seq with attention 
wrapper in encoder 
0.284 0.073 
seq2seq with attention 
wrapper in decoder 
0.282 0.071 
 
Chapter 3.2: Running the Three Approaches on CHF Dataset  
 
Chapter 3.2.0: Introduction 
 
The Cerner Health Facts database is a real-world, de-identified, HIPAA-compliant electronic 
health records (EHR) database. The data in this database represents the care delivered by 
participating Cerner client hospitals and clinics that agreed to share the data for research purposes. 
All identifiable patient health information was removed from the database to accelerate the 
research. The Cerner Health Facts (CHF) is a comprehensive dataset, unlike claims data, which 
primarily covers billing data. The CHF dataset provides complete details such as encounter facts, 
diagnosis facts, procedure facts, medication facts, laboratory facts, microbiology facts, and other 
information. Each Patient in the CHF dataset has a unique identifier. The unique identifier is the 
identifier that can track a patient over different hospitals or insurance programs. For this research, 
I used the Cerner 2015 dataset, which enrolled 49,826,219 unique patients with 2.7 billion clinical 
events from 2000 to 2015. Six hundred fifteen (615) hospitals were represented in this dataset. In 
order to achieve the goal of this research, I used patients who had at least five years of records. 
The inclusion criteria identified 2,129,885 patients. After the data-cleaning process, there were 
1,401,676 patients still in this research. There were 1,247,541 non-T2DM patients, and 154,135 





Chapter 3.2.1: The Demographic Information of CHF Datasets 
 
The following sections will illustrate the demographic constitution, the frequency of diagnosis, 
medications, laboratory work, and vital signs. This section will also provide the proportion of 
missing values of some essential measurements such as height, weight, and blood pressure in both 
datasets. The first section includes a summary of demographic information regarding the two data 
sets. The demographic information includes race, gender, and age when enrolled in this dataset.  
 




Fig. 16A is the race proportion of CHF’ dataset; the figure excluded race below 1% of the dataset. 
Fig. 16B is the gender proportion of CHF’ dataset; the figure excluded gender below 1% of the 
dataset. Fig. 16C is the age proportion of CHF’s dataset. 
 
3.1.2.2: The Information of Years of Data of CHF 
From Figure 17, the patient with years of data sees a drop over the years. More than half of the 







Figure 17. The Summary of Proportion of Patient with Datum Over Years - CHF 
 
 
Chapter 3.2.2: Methods 
The methods of validation used included three types of temporal representations as well as the 
UTP dataset. Please refer to all methods in Chapter 3.1.2.  
Chapter 3.2.3: Findings 
 
Chapter 3.2.3.1: The Summary of the CHF dataset 
 
In this table, we can find the T2DM patients in CHF’s dataset with shorter enrolled years. T2DM 
patients will still be elderly and higher weight than non-T2DM patients. The records of blood 
pressure showed no significant difference between T2DM and non-T2DM patients.  
 
Table 18. The Summary of CHF Dataset 
Cerner Health Facts T2DM (Mean/ S.D.) Non-T2DM (Mean/ S.D.) 
Enrolling year 4.478/5.754 year 5.675/2.627 year 
Enrolling age 57.23/16.11 year 44.35/23.79 year 
Gender Ratio Female: 68.1 % /Male: 31.9% Female: 61.2 % /Male: 38.8% 
Weight 88.13/31.66 Kg 69.58/32.37 Kg 
Systolic 127.83/24.25 mmHg 122.04 /22.41 mmHg 
Diastolic 70.38/14.75 mmHg 69.90 /14.75 mmHg 
 
Chapter 3.2.3.2: The Summary of Top Variables over Different Data Types – CHF 
 
In the previous section, I introduced some differences which might affect the performance of the 
prediction model, for more detail presenting the differences between the T2DM and non-T2DM 
patients in the CHF dataset. In this section, I will present the differences in diagnosis, medications, 
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unspecified essential hypertension and unspecified hyperlipidemia. There was no significant 
difference in diagnoses of malaise and other fatigue, long-term records of medication, and 
abnormal pain between T2DM and non-T2DM.  
The information, generally speaking, was the essential factor in most prediction models. The 
records of several basic and regular measurements of EHR were missing such as weight, systolic 
blood pressure, diastolic blood pressure, and height. This might introduce some strong limitations 
in applying those prediction models to the EHR system.  
All relevant information in this regard is in Figure 18. 
Figure 18 . The Summary of Top Information Rich Variables - CHF 
 
Chapter 3.2.3.3: The Conventional Model Performance – CHF 
 
All settings and variables in the conventional model of CHF were as good as the UTP dataset. In 
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Table 19 . The Summary of Patient Number at Cutting Points Scheme-CHF 
Cutting time points  T2DM  Non-T2DM  
One year  153,269 1,243,395  
Two years 152,616 1,241,222 
Three years 113,551 1,178,534 
Four years 80,508 1,084,310  
Five years 52,881  835,030 
 
Based on figure 19, the pattern of patients with records of selected variables is similar to the UTP 
dataset. The conventional model performance is as weak as the UTP dataset (Table 20). This 
implies that the bigger dataset with poor data quality still cannot improve performance. It also 
implies that we should use other methods to overcome the limitations. 




Table 20.  The Performance of Conventional Model at Cutting Points Scheme-CHF 
Cutting time points  AUC ACC  
One year  0.497  0.448  
Two years 0.497 0.524 
Three years 0.498 0.526 
Four years 0.501 0.502 
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Chapter 3.2.3.4: Non-temporal and Temporal Representations Performance – CHF 
 
From the results of non-temporal and interval-temporal representations of CHF, the performance 
was better than the performance of UTP, but it was limited. In all the testing of the machine 
learning algorithms, logistic regression was still the best in both non-temporal (Figure 20) and 
interval-temporal representation (Figure 21). The next two machine learning algorithms were 
random forest and support vector machine. In continuous-temporal representation, I used the RNN 
as the testing algorithm. The performance of continuous-temporal representation was much better 
than non-temporal and interval-temporal representation (Figure 22). If the model used the larger 
dataset, the performance was improved in a limited way.  
Figure 20.  The results of Non-Temporal Representation - CHF  
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Figure 22. The Results of Continuous-Temporal Representation - UTP & CHF 
 
Chapter 3.2.3.5: Random Split Model Performance – CHF 
 
Table 21includes the average year of data in the encoder and decoder and the age in the CHF 
dataset. However, in the all patients dataset, the T2DM patients had shorter years of data in both 
the encoder and decoder.  
Table 21.The Basic Information of Random Split Scheme - CHF 
Cerner Dataset 
(All Patients) 











Non-T2DM  1,221,979 (2.10 /1.91)  (3.07/1.90)  (44.5/23.8) 
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Non-T2DM  437,722 (4.22 /1.43)  (2.21/1.42)  (44.4/23.3) 
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Figure 23.The Outputs of the seq2seq Model 
 
Figure 23 presented the outputs of the seq2seq model of T2DM and non-T2DM patients. For 
T2DM patients, the outputs of the model fulfill our original design. There was some noise in the 
projection part (dashed line) of non-T2DM patients. In Figure 23, both points have meaning. For 
T2DM patients, the point indicated the time point of the receiving T2DM diagnosis, and for non-
T2DM patients, it represented the time point of the last visit. The solid line indicated knowledge 
of the health condition of the patient and the dashed line represented lack of knowledge about the 
health condition. 
In Table 16, I listed the performance of non-temporal representation, the performance of random 
split using all patients and those with at least three years of data in the encoder. By using the 
patients with more years of information in the encoder, the performance was better than using 
patients with fewer years of information in the encoder. It seems that the attention mechanism did 









Table 22. The Performance of Random Split Scheme - CHF 





Seq2seq (encoder attention) 0.884 
Seq2seq (decoder attention) 0.898 
 





Seq2seq (encoder attention) 0.917 
Seq2seq (decoder attention) 0.918 
 
In Table 22, I listed the performance of non-temporal representation, the performance of random 
split using all patients and those with at least three years of data in the encoder. By using the 
patients with more years of information in the encoder, the performance was better than using 
patients with fewer years of information in the encoder. It seems that the attention mechanism did 
not improve the performance of our experiment. 
 
Table 23. The MAE of Random Split Scheme - CHF 
Continuous: Cerner_all 
Seq2seq 0.294 0.069 
Seq2seq with attention 
wrapper in encoder 
0.298 0.075 
Seq2seq with attention 
wrapper in decoder 
0.293 0.072 
Continuous: Cerner_ encoder_year over three years 
Seq2seq 0.310 0.072 
Seq2seq with attention 
wrapper in encoder 
0.312 0.077 
Seq2seq with attention 
wrapper in decoder 
0.313 0.074 
 
In Table 23, I used MAE to estimate the performance of early detection of T2DM. From this 
perspective, the MAE of T2DM patients should be much higher than that of non-T2DM patients. 
The results met my expectations but using patients with more information in the encoder did not 
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improve the performance. Thus, the attention mechanism makes no difference in the performance 
of the early detection of T2DM. 
 
Figure 24. TimeROC of UTP and CHF 
 
Figure 24 represents two settings. The first setting is using the patients who had at least two years 
of data with at least one year in the encoder and at least one year in the decoder. The second setting 
is patients who had more than three years of data in the encoder. The results in the UTP dataset 
indicated that the seq2seq model with the decoder attention mechanism had the best performance. 
The performance of seq2seq without the attention mechanism was next, and the third was the 
seq2seq model with encoder attention. The results in the CHF presented the same trend but had 
some noise.  
Chapter 3.3: Discussion and Comparison  
 
Chapter 3.3.1: The Comparison of Demographic Information Between Two Datasets  
 
Based on the demographic information from these two datasets, there were some differences 
between the two datasets. The first is that CHF had a higher proportion of Caucasian people 
compared with the UTP dataset. In addition, CHF had more patients whose age when entering this 
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dataset was over 65.  More interesting is that the UTP dataset had more other races compared with 
the CHF dataset. Both datasets had more female patients than male patients. 
Chapter 3.3.2: The Comparison of Patient with Datum Over Years Between Two Datasets 
 
Comparing UTP and CHF, the patients in the CHF dataset had more years of data than the UTP 
dataset. Whether the information is useful for developing a T2DM prediction model requires 
further examination. 
Chapter 3.3.2: The Comparison of Patients Detail Between Two Datasets 
 
For comparing T2DM and non-T2DM groups, I chose the top ten variables which most patients 
have. From those variables, we can build general information about the two datasets from 
diagnosis and medications to labs and vitals. From the perspective of diagnosis, under the local 
level, T2DM patients received more diagnoses of hypertension, chest pain, abdominal pain, and 
shortness of breath. At the national level, T2DM patients suffered not only hypertension but also 
hyperlipidemia. Additionally, T2DM patients had more records of long-term medication usage. In 
the records on medications, in the UTP dataset, most prescriptions were aspirin because UTP is 
the local primary care hospital. CHF, on the other hand, presented a more diverse phenomenon: 
more prescriptions, such as nonsteroidal anti-inflammatory drugs (NASID) and some opioid drugs, 
including fentanyl and morphine. In chronic conditions, UTP data presented T2DM patients with 
more chronic diseases, such as asthma, conduction disorder, cardiac dysrhythmia, and 
hypertension. The CHF dataset only showed that T2DM patients had more records of hypertension 
and hyperlipidemia. In datasets of records of labs and vitals, more (half of) non-T2DM patients 
received a complete blood count test as well as T2DM patients. In a good practice, those basic 
vital signs were measured and documented in the EHRs. These records may have been paper-based 
and were not recorded into EHR. The more interesting part is the high proportion of the missing 
value of weight and height. This phenomenon might corrupt the performance of the general model 
for detecting T2DM patients using a conventional model.  
 
Chapter 3.3.3: The Discussion Between Two Datasets 
A. The Possible Explanation of the Performance  
Based on Figures 14, 15, 20, and 21, the interval-temporal representation improves a limited 
performance compared with the non-temporal representation. This implies that the information for 
building a prediction model is insufficient or irrelevant to the target I chose, which means I did not 
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have enough information to make a prediction. This explanation can be supported by the UTP, 
single medical center, which presented a worse performance compared with the CHF (multiple 
centers) dataset. Having enough information does not mean having more records but means having 
high-quality information. The high-quality information comes from well-managed data that can 
track what information should be collected and be documented. Unfortunately, both datasets did 
not qualify for the definition, as they had irrelevant information and corrupted the performance of 
the prediction model. For example, whether the patient came to a vaccine check is irrelevant to 
this research prediction model.  
Deep learning provides an alternative way to overcome limitations such as insufficient or irrelevant 
information and achieve an acceptable performance (Figure 22). However, deep learning is a more 
data-driven method that can be highly affected by the data we put in. The other problem is that 
deep learning cannot provide a constant and reliable explanation for why the outcome should be 
as the model predicts.  
B.  The Solution and Explanation of the Continuous Outputs by the seq2seq Model  
 
In Figure 23, I demonstrated the seq2seq model that combines the random split scheme to 
overcome the limitation mentioned in the previous section. The outputs, generally speaking, are 
reasonable but still have some problems. The first issue is the noise that increases sharply and then 
drops down quickly in the non-T2DM patients. The noise happens in the projection part, where 
the model estimates the possibility of an unknown future for a given non-T2DM patient. As 
previously mentioned (Figure 10), a random split scheme randomly separates a patient's 
information into an encoder and decoder, and seq2seq outputs a sequence that represents a 
possibility of each point of a fixed period (e.g., the annual possibility of developing T2DM in the 
next ten years). This condition implies that, after a specific time point, the patient has no further 
information, especially the non-T2DM patient. For the no further information part, I called this the 
projection part. In the projection part, the seq2seq model still needs supervised labels. For T2DM 
patients, the labels represent T2DM, and non-T2DM patients represent non-T2DM.  This is still a 
challenge, and I can try other newly developed seq2seq models or other deep learning methods, 
such as a drop out mechanism which removes the connections[178] or the neurons[179] or freezing 
the weight[180]. 
On the other side, I can go back to what happened in the encoder, which is the information 
processor extracting and generating the representation from the decoder to the project. As we all 
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know, EHRs are a complex dataset and incorporate a lot of bias. The deep-learning model has been 
proven as a way to handle the complex dataset. In this research, I used a simple RNN and attention 
mechanism in the encoder or decoder, which assists the model in extracting essential information 
to build the final state for the decoder to project. As the results in Table 19 show, simple RNN 
outcompetes the performance while using an attention mechanism. From the result, I cannot 
conclude the attention mechanism is not useful because I did not try all attention mechanisms. 
However, we need to check some experiment design problems. I aggregated the information 
annually and entered the dataset to the patients’ final date in the dataset. This design can hold real-
time information among medical events. I did not create the order of each event in each period, 
through which some medical information could be inferred (e.g., Hba1c before the T2DM 
diagnosis). I can apply a shorter period for each patient but also introduce more zero values. Based 
on the previous study, the permutation of the order of a patient’s history did not change the 
performance of the model, but adding or deleting patient history alters model performance [181]. 
The result implies that we might change the order of healthcare events within the period and train 
pre-embedding for reducing the noise. Another study also pointed out that acute conditions tend 
to offer fewer opportunities to be predictable because of their spontaneous occurrences[182]. 
Removing the acute conditions might be an alternative solution.  
 
My model treats the information in the EHRs, such as diagnosis, medications, or lab results, as a 
word in a sentence or in a paragraph, which is the full information of a given patient. The context 
of that information is not as strong as the real text documents. Patients might receive a diagnosis 
first and then another diagnosis later. For clinicians, both diagnoses might not have temporal 
correlations but may have just happened recently. The attention mechanism might highlight them 
as important information. If the dataset had more information, those false temporal correlations 
might also increase. This correlation corrupts the whole performance. This explanation can be 




Chapter 4: Identifying the pattern or algorithms to early identify 
T2DM patients  
Chapter 4.0: Overview 
 
In Chapter 3, this dissertation explored the performance of different types of temporal 
representations combined with different kinds of machine learning algorithms. In this chapter, this 
dissertation wants to explore some possible patterns which can develop early identification 
solutions to prevent T2DM. In the beginning, I will introduce some methods used to explore the 
original dataset. Then, I will examine the variables identified by the machine learning algorithms. 
Finally, I will discuss the limitation of current machine learning algorithms on EMR/EHR research.  
 
Chapter 4.1: Examination of The Original Datasets 
Chapter 4.1.0: Introduction 
 
Because T2DM is a chronic disease that needs a long time to develop, this implies that chronic 
conditions contribute more to developing T2DM. Others, like long-term medication use, is another 
aspect worthy of consideration. The limitation in this research is we only have the date of 
prescriptions and estimation of refill times, but we lack other information from the pharmacy 
which can indicate when and what types of drug this patient received. Lab and vital signs still lack 
long-term tracking for patients; this is why I discarded them in this section. For exploring the 
chronic conditions, I adopted two types of methods. The first is under the cutting-point scheme, 
using biology network to present the interaction among chronic conditions. Then, I used chronic 
condition indicators as a variable for using survival analysis to evaluate the relative importance.  
Chapter 4.1.1: Methods 
 
Chapter 4.1.1.0: The Biology Network 
 
I also explored the interactions among different chronic conditions between the T2DM group and 
the non-T2DM group because some combinations of the chronic conditions might be more 
prevalent in T2DM patients than non-T2DM patients. Based on this reason, I profiled the 
interactions at each time point of the cutting-point scheme. The greater width of each line indicated 
that the interaction between the two variables is more prevalent in the T2DM group than the non-
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T2DM group. The threshold set is three, which means the interaction between two chronic 
conditions is three times more frequent in the T2DM group than in the non-T2DM group. 
 
Chapter 4.1.1.1: The Statistical Methods  
 
One of the most significant gaps between clinical research and data-mining fields is extending the 
current knowledge based on the findings from the results of the data-mining fields. Considering 
T2DM is a chronic condition, most research for developing T2DM prediction models is based on 
survival analysis because of time-to-event research. The covariates in this study are the chronic 
condition indicators, and we realized the chronic conditions were varied by time. Under this 
consideration, I used the Cox proportional time-varying model[184]. 
 
A survival analysis must address 1) event, 2) time, and 3) censoring. In this experiment, the event 
occurred when this patient was diagnosed with T2DM. Time is the entire observation period of the 
patient. In the definition of a survival analysis, censoring is a condition that is partially known in 
the research. In this research, the conditions of only non-T2DM patients were known before the 
last time of visit. After that time point, I did not know the conditions of those patients. The time 
after the last time of visit is called censoring.  
 
There are several limitations of this experimental setting. The covariates of this survival analysis 
were chronic condition indicators based on ICD-9-CM. Because of the chronic conditions’ varying 
by time, I adapted the Cox time-varying model to handle this problem. Considering T2DM is an 
age-associated chronic disease, the survival analysis was performed on all patients in the following 
three age groups: 1) age over twenty and below forty, 2) age over forty and below sixty, and 3) 
age over sixty. 
 
Chapter 4.1.2: Findings 
 
Chapter 4.1.2.1: The Chronic Condition Indicators Net  
 
In Figure 25 from the upper left, upper right, down left, and down right, representing four different 
time points before the end date of the study, coronary atherosclerosis had the most connections 
over four time points.  When starting from the earliest time point, four years before the end date, 
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coronary atherosclerosis still had several contacts with other chronic conditions, including 
hypertension, hyperlipidemia, other central and peripheral nervous system disorders, congestive 
heart failure, asthma, cardiomyopathy, structural heart disease, and sleep disorders. When 
approaching a later time point, coronary atherosclerosis had more connections with other chronic 
conditions. The phenomena implied that coronary atherosclerosis might be the most common and 
concurrent chronic condition with other chronic diseases. 
Figure 25. Chronic Conditions Indicators Net - UTP 
 
 
When I examined and applied the same threshold to a national-wide dataset, Cerner Health Facts 
(Figure 26), the data represented a different pattern. Both chronic pancreatitis and obesity are the 
hubs that connect other chronic conditions. 
 62 







Chapter 4.1.2.2: Exploring the High Risk Chronic Conditions from Survival Analysis 
 
The odds ratio of all chronic conditions of patients whose age (above twenty) indicated obesity, 
hypertension, and tuberculosis were the top three risk factors of developing T2DM in the UTP 
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dataset. Chronic pancreatitis and liver diseases were the next highest risk factors. After stratifying 
by age, chronic pancreatitis, gout, and cystic fibrosis were high-risk factors for the patient in group 
one. Cystic fibrosis had no statistical significance. Middle-aged patients with tuberculosis or 
hypertension had the highest odds ratio of developing T2DM. The third-highest risk factor is liver 
function. In more elderly patients, TB, obesity, and chronic pancreatitis were the top three risk 
factors.   
Figure 27. Results of Cox Time Varying Model - UTP 
 
 
Because UTP is a regional primary care clinic, the phenomenon presenting in this dataset may not 
be generalized to the national level. To explore the difference between the local and national levels 
more accurately, I performed the same analysis on the CHF dataset. The results presented a 
different landscape. For adult patients, at the national level, obesity and chronic pancreatitis were 
both serious risk factors. The next-highest risk factors were chronic liver disease and chronic renal 
failure. TB may have still been a high potential risk factor but lacked any statistical significance, 
but when we focused on the younger adults, cystic fibrosis and TB were the most two influential 





























































































































Odds Ratio of CoxTimeVaryingFitter utp_3_cut
Young Adults Mid-ages Adults Elderly Adults
 64 
patients, obesity and cystic fibrosis were the top two risk factors. Our results for elderly patients 
showed that obesity and chronic pancreatitis were both notable risk factors.  
Figure 28. Results of Cox Time Varying Model - CHF 
 
Chapter 4.1.3: Discussion: 
 
The difference in CCIs between UTP and CHF results in the following findings. Because UTP is 
a local primary care center whose patients were transferred to other hospitals, the information is 
insufficient. The CHF collected more information on a patient because it is a multiple-center 
dataset. However, I need to point out that hospitals joined the CHF system in different years and 
that not all hospitals participated. Even though the information is more complete in the CHF dataset, 
when a center joined CHF for data sharing still needs to be considered. 
 
The biggest question that previous figures cannot answer is: When a patient had several chronic 
conditions, which patients had higher risks of developing T2DM than others? As previously 
mentioned, EHR is a longitudinal record, and T2DM is a time to event question. Survival analysis 
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survival analysis cannot be workable. This is why I adopted the Cox time-varying model to answer 
it. I stratified the whole population into three subgroups—younger adults, middle-aged, and older 
adults—over two datasets.  In UTP datasets, chronic pancreatitis is the number one risk factor in 
young adults. Based on current research, recently, some experts defined a new type of diabetes 
called type 3c DM. Chronic pancreatitis, cystic fibrosis, and pancreatic resection cause type 3c 
DM[185]. In this research, the prevalent age group of chronic pancreatitis was middle-aged people, 
which is not consistent with the result; this implies we need more research. The younger adult 
patients in CHF with cystic fibrosis had the highest risks of developing T2DM, which meets the 
description of the research[185]. Another study indicated that type 3c might happen at any age 
along with nutrition deficiency, such as Vitamin D deficiency,  and with presenting osteoporosis 
or osteopenia [186]. Based on the findings, we can conclude that we need more research for type 
3c diabetes in younger adults because this type of DM does not separate currently from T2DM in 
this research.  
 
Chapter 4.2: Examination of the Variables Learned by Machine Learning 
Chapter 4.2.0: Introduction 
I also used permutation importance to evaluate the variables learned by machine learning (ML) 
methods and extraction; some of them were reliable for further examination. Considering the 
guideline effects, which can cause undiagnosed diabetes, which might corrupt the reliability of the 
model, I set up an experiment to indicate its effects. 
 
Chapter 4.2.1: Methods 
 
Chapter 4.2.1.1: The Evaluation of Variable Importance 
 
One of the challenges of implementing current machine learning algorithms over the real clinical 
world is not on the performance of the model but on what kind of information is utilized by the 
model. In this dissertation, I used three types of temporal representation, which can learn a portion 
of information from data. The weight matrix from machine learning algorithms can indicate the 
importance of a variable related to T2DM or not. Because this is a binary classification problem, 
the weight above zero is supposed to correlate with T2DM while below zero is not related to T2DM. 
Continuing from the previous performance results, I chose the weight matrix from logistic 
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regression to extract variable information from non-temporal representation and interval temporal 
representation. The embedding layer is the layer of deep learning models that used to represent the 
high dimensional inputs from datasets. Extracting the information from the embedding layer can 
represent what a deep learning model learns from the dataset. Each type of temporal representation 
chose the top 5% of variables and extracted data from the original dataset. The data was separated 
into two parts: categorical variables including ICD-9-CM/PCS codes, medications, and procedures 
and numeric data, such as laboratory results and vital signs. All of them ran on permutation 
importance separately and chose eighty percent higher than the null distribution. The final two 
figures represented the important variable, which might be used for further discussion regarding 
the clinical meanings. 
Chapter 4.2.1.1: The Evaluation of Some Possible Lab Tests for T2DM Screening 
I conducted an experiment to determine whether a clinician being given abnormal lab results would 
consider this an indication to perform HbA1c on a patient. HbA1c is the regular test for diagnosing 
T2DM, so if the abnormal lab results cannot remind clinical practitioners to perform HaA1c tests, 
those patients might become undiagnosed T2DM patients. If the proportion of undiagnosed T2DM 
is high, this will corrupt the reliability of the model.  There were several considerations before this 
experiment. The first is the index date for the patients. The index date for non-T2DM patients is 
the last visit, and for the T2DM patients, it is the first date when they started T2DM medications, 
received the T2DM diagnosis, or had a finding above the threshold plasma glucose. I collected the 
information within one year before the index date for a given lab test. The violin plots ( Figure 31-
Figure 40) are to present the distribution of a given lab test. A threshold of the lab test is set up to 
separate normal and abnormal results. I calculated the relative risk of T2DM when patients already 
had abnormal lab test results. The relative risk was calculated by following four groups: 1) age 
above twenty; 2) age above twenty and below forty; 3) age above forty and below sixty; and 4) 
age above sixty. I normalized the relative risk of the group with age over twenty as one and 
compared it to the other three groups. Then, I calculated the relative risks of the four previously 
mentioned age groups that received HbA1c tests and did not receive HbA1c tests within one year 
before the index date. If the relative risk of the group receiving the HbA1c tests is higher than the 
group not receiving HbA1c tests, it implies that the abnormal records of this lab test might be 
associated with HbA1c tests under current clinical settings. If not, it is irrelevant to current clinical 
settings. 
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Chapter 4.2.2: Findings 
 
Chapter 4.2.2.1: The Results of Variable Importance 
From the results of the permutation test of categorical data, it is recommended that people with 
several known risk factors such as hypertension (HTN), hyperlipidemia disorder (HLD), and 
obesity should be screened. Some highly correlated risk factors like chronic heart disease (CHD) 
and non-cardiac congenital disorder were also selected. Some signals were needed for further 
investigation such as other abnormal blood chemistry (OABC), vitamin D deficiency, and fever, 
among others. Some of them might be worthy of researching, and others might not be (Figure 29).  
In lab and vital signs, HbA1c and glucose were the top two variables associated with T2DM. Some 
variables such as absolute lymphocyte count, alkaline phosphatase, prothrombin time (PPT), 
creatinine serum, and glomerular filtration rate were usually tested but currently are not listed in 
the ADA primary care diabetes screening guideline. Triglyceride serum and HDL serum were both 
reliable indicators for supporting performing HbA1c on patients (Figure 30).  
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Figure 30.Permutation Importance Results-Numeric 
 
Chapter 4.2.2.1: The Results of Some Possible Lab Tests for T2DM Screening 
Figures 32 and 33 are HDL and Triglycerides (TG). In the violin plots ( Figure 31-Figure 40), 
T2DM patients had higher TG and lower HDL, and younger adults (20<=age<=40) had higher 
relative risks in TG, which is above 200 milligrams per deciliter and HDL below 40 milligrams 
per deciliter. The group undergoing HbA1c test had higher relative risks compared with the group 
did not take HbA1c test. This implies that when clinical practitioners see abnormal results from 
both tests, they usually order HbA1c within the same period that is suggested by the guideline. 
This is why the relative risks are higher in the HbA1c group than in the non-HbA1c group. 
 
When we move forward to thyroid-stimulating hormone (TSH) (Figure 34) and lymphocyte count 
(Figure 35), patients had abnormal results, and relative risks were higher in younger adults than in 
other groups. Lower relative risks were identified in groups that did not receive HbA1c tests. This 
implied that the current clinical system might consider the abnormal signal of the two lab tests as 
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Young and middle-aged adults with abnormal SGOT, above 147 units per liter (Figure 36), or 
SGPT, above 55 units per liter (Figure 37), easily received T2DM diagnosis within one year, and 
most of the patients did not undergo HbA1c test in the same period. This result implied that the 
current clinical system did not consider them as the signal for HbA1c testing. Without the HbA1c 
test, we could not correctly examine the present or future risks of T2DM. This result also indicated 
that SGOT and SGPT might be a new proxy for further exploring the criteria for HbA1c screening. 
In albumin serum (Figure 39) and creatinine (Figure 38), serum presented a similar pattern like 
SGOT and SGPT if the patient who had abnormal records (creatinine: above 1.2 milligrams per 
deciliter; albumin: above 5.5 grams per deciliter) received less HbA1c screening. Behind this 
phenomenon, there might be some reasons for further explanation. Glomerular filtration rate (GFR) 
(Figure 40, 41) is an indicator to examine the renal function. In our results, it also showed the same 
pattern as creatinine and albumin. We also need to take into account that the average value of the 
two groups is lower than the standard threshold (90 milliliters per minute per 1.73 square meter). 
It might imply when patients receive this lab test with some abnormal renal function. 










Figure 32. Results of HDL 
 
 
Figure 33. Results of TSH 
 




Figure 35. Results of SGOT 
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Figure 37. Results of Creatine 
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Figure 38. Results of Albumin 
 
 
Figure 39. Results of GFR-1 
 
Figure 40. Results of GFR-2 
 
 73 
Chapter 4.2.3: Discussion 
 
From the results in Figure 29, I found some of the medical conditions learned by ML were merged 
with the high-risk conditions based on survival analysis. For example, Vitamin D deficiency is one 
types of symptoms of malnutrition.  The reason is in each type of temporal representation; we used 
all available information. Using full information can improve performance but can also introduce 
unnecessary information. The unnecessary information not only can reduce the performance of the 
model but also can lead to a model which is hard to interpret. In the future, using the survival 
analysis to identify some high-risk conditions and selecting the related variables might be more 
helpful. 
Figure 30 presents some lab tests that might be useful for the prediction of T2DM and non-T2DM. 
Based on the information from Figure 30, I chose several variables for further analysis. From the 
results, I found that the risk factors such as hyperlipidemia (Figure 32) or a low proportion of HDL 
(Figure 33) recommended by the ADA usually remind clinicians to order HbA1c tests for 
screening. This is why the relative risks of the variables are higher in patients who have completed 
HbA1c testing than in patients who have not. TSH is usually considered with metabolism [187], 
which is one of the risk factors associated with T2DM. This is why TSH has a pattern that is similar 
to that of hyperlipidemia. Other abnormal lab results from SGOT, SGPT, creatinine, and GFR 
cannot remind the real clinical world to screen patients who might be at higher risk than 
undiagnosed patients because these are not included in the current screening guideline.  But we 
















Chapter 5: Conclusions, Limitations, Synthesis, and Future Work 
 
Chapter 5.1: Conclusion 
 
Chapter 5.1.1: The Conclusion of Temporal Representation 
 
For the performance of two testing schemes and three types of temporal representations, 
continuous representation performs better than, the other two types of temporal representations in 
the cutting time points scheme. For the random splits scheme, our seq2seq model had a better 
performance than the other two widely used models—one is RNN, and the other one is RETAIN. 
To realize the extra data effects more, which means more years of data in the encoder, I made a 
threshold wherein a patient must have at least three years of data in the encoder. From the result, 
the patient had a better performance than those with less data in the encoder. Besides, I used MAE 
to measure the early detection of T2DM patients in the seq2seq model, which presented the larger 
dataset with a better performance. In the research, I want this model not only to predict whether 
the patient had T2DM or not, but also when this patient had T2DM. To achieve this goal, I adapted 
the time ROC to measure it. The results presented an interesting phenomenon where the seq2seq 
model without attention mechanism in the encoder or decoder had a better performance. In addition, 
the noise in the larger dataset, which came from patients that had shortened periods of records, 
decreased the performance of the model. There were many reasons why the patient did not have 
enough data for this analysis and research.  
 
Chapter 5.1.2: The Conclusion of the Information Learned by Data 
This research also wants to determine how the machine learning algorithms learned from the data 
and the difference between the information learned by the machine learning algorithms and the 
information learned by traditional biostatistics. The traditional biostatistical method such as 
logistic regression and survival analysis had been widely applied to data analysis to summarize 
some information, which can suggest some modifications of guideline or policy changes. The 
machine-learning algorithms, on the other hand, learned the patterns in the data and used the 
pattern to predict the patients’ risks. This research also wants to identify this gap and point to an 
alternative direction to solve this problem and make machine learning applicable to the real clinical 
world in the future. T2DM is a chronic disease, and before developing it, patients underwent some 
conditions that contribute to developing T2DM. Chronic condition indicators can catch those 
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conditions. Using chronic condition indicators, we can demonstrate what kinds of chronic 
conditions were more prevalent in the development of T2DM by using survival analysis. In the 
survival analysis, we found the most critical chronic conditions among different age groups were 
different in the two datasets. The difference implied that the local group had significantly different 
characteristics from the nation-wide group. This might imply that the model training based on the 
local dataset cannot be used in the national dataset. However, the difference is useful for building 
the prevention policy for intervention. In the future, when we want to design a model for clinical 
usage, the difference might assist us in estimating the changing algorithm effects. 
 
Chapter 5.1.3: The Suggestion for Considering the Guideline Effects 
 
For testing this assumption, I used the results of lab tests within one year before the index date. I 
also tested some lab results which were based on temporal representations; the models believed 
those variables were highly associated with T2DM. From the results, TG and HDL meet my 
assumptions. TSH is the variable that is not listed in the recommendation guideline but still has 
high relative risks in patients who had HbA1c tests rather than patients without the HbA1c test. 
The result indicates that clinical practitioners seeing the abnormal results of TSH might order the 
HbA1c test in the same period. The results cannot explain why and how they do this, but we can 
further research this phenomenon. GFR, albumin, creatinine, SGOT, and SGPT presented lower 
relative risks in patients with an HbA1c test than patients without the HbA1c test; this implies that 
abnormal results with those two tests do not urge clinical practitioners to order HbA1c. We can 
further infer that ignoring those abnormal signals might cause undiagnosed T2DM. The patients 
with undiagnosed T2DM might corrupt the data reliability and cause more noise in the model.  
 
Chapter 5.2: Limitations 
 
Except for the differences in the dataset, we need to consider that another issue is the guideline. 
The guidelines construct the screening process, which determines the classification of the label. 
The ADA T2DM screening guideline recommends that patients over 40 with some symptoms, 
such as hypertension or hyperlipidemia, are worthy of receiving HbA1c screening. This means 
that patients with other abnormal lab tests usually did not receive HbA1c screening. Besides, 
HaA1c is the lab test for diagnosing T2DM. The guideline based on this might lead to undiagnosed 
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T2DM, which will make the prediction model lose focus on some T2DM-related information and 
further reinforce the bias.  
 
Chapter 5.3: Synthesis 
 
In this research, I found some possible risk factors associated with T2DM. Chronic pancreatitis is 
the top risk factor in young adults in this research. Based on current research, some experts defined 
a new type of diabetes called type 3c DM. Type 3c DM is caused by chronic pancreatitis, cystic 
fibrosis, and pancreatic resection[185]. In this research, the prevalent age group of chronic 
pancreatitis comprised middle-aged people, which is not consistent with the result. This suggests 
that we need more research. The younger adult patients in CHF with cystic fibrosis had the highest 
risk of developing T2DM, which meets the description of the research[185]. Another study 
indicated type 3c might happen at any age by accompanying nutrition deficiency, such as Vitamin 
D deficiency, and presenting osteoporosis or osteopenia [186]. Based on the findings, we can make 
a conclusion that for type 3c Diabetes in younger adults, we need more research because this type 
of DM currently is not separated from T2DM.  
The association between TB and T2DM is still an interesting question. Some researchers focused 
on patients with T2DM likely to develop TB rather than developing TB first then developing 
diabetes[188]. In this research, I still hold the question about this association because I did not find 
the same pattern in the CHF. It might be a local issue (Texas only) or some problem with data 
collection. 
Liver diseases still have a strong correlation with the development of T2DM, but this lacks 
substantial evidence[189]. Recently, research pointed out non-alcoholic fatty liver disease 
(NAFLD) and type 2 diabetes (T2DM) are common conditions that regularly co-exist [190]. This 
is an interesting question to answer determining whether liver disease causes T2DM, or is just a 
side-effect of T2DM; this is still a question. Our dataset is limited by the data collection method, 
which cannot answer this question. 
 
Chapter 5.4: Future Work 
The Food and Drug Administration (FDA) recently opened a panel to discuss the regulation of 
Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD)[191]. In FDA’s 
definition, SaMD is software independent from the hardware medical devices for achieving some 
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medical purpose, including treatment, diagnosis, cure, and mitigating or preventing diseases or 
other conditions[191]. One of the issues of AI/ML that the FDA is concerned with is the model 
retraining. From the traditional perspective, the medical device can generally work on the 
condition that it is FDA recognized and approved. The AI/ML models are data-driven applications, 
and EHR data is recognized as full of bias and errors. Additionally, bias and errors are also affected 
by education and the culture of an organization. This means that the AI/ML model needs to retrain 
in the new environment. The process of retraining can alter the weight of variables, the contents 
of AI/ML, and cannot prove to the FDA that the retraining model is the same as reported in the 
pre-market submission. The FDA is skeptical about this process because it might affect the model 
reliability, especially of some models that are based on the neural network.  To resolve this issue, 
the FDA proposed a framework that requires SaMD not only to provide the pre-market document 
for demonstrating its effectiveness and safety but also to give the expected algorithm’s changed 
protocol after retraining. The American Medical Informatics Association (AMIA) generally agrees 
with the FDA’s proposed framework but approves of more advanced regulation of continuous 
learning algorithms (deep learning). AMIA also advocates determining how to control the new 
data input because this will alter the contents of the AI/ML model and how the knowledge will 
affect the data collection process, which will change the dataset for retraining [192].  
From this perspective, the future of medical AI should be based on more reliable datasets such as 
those found in certified EHRs. The certified EHR contains the standardized data element. Even 
though the data element might be different in different hospitals, under the same standards, we can 
estimate the differences and design some experiments to test how those differences may or may 
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